Marizyme (MRZM) 10-K 31 Mar 22 2021 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2022	Jun. 30, 2021
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	000-53223
Entity Registrant Name	MARIZYME, INC.
Entity Central Index Key	0001413754
Entity Tax Identification Number	82-5464863
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	555 Heritage Drive
Entity Address, Address Line Two	Suite 205
Entity Address, City or Town	Jupiter
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33458
City Area Code	(561)
Local Phone Number	935-9955
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 8,543,150
Entity Common Stock, Shares Outstanding		40,828,188
Documents Incorporated by Reference [Text Block]	None
ICFR Auditor Attestation Flag	false
Auditor Firm ID	100
Auditor Name	WithumSmith+Brown, PC
Auditor Location	Whippany, New Jersey

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Current
Cash	$ 4,072,339	$ 2,902,762
Accounts receivable	8,650	40,585
Other receivables	41,307
Prepaid expense	257,169	106,390
Inventory	22,353	56,340
Total current assets	4,401,818	3,106,077
Non-current
Property, plant and equipment, net	12,817	7,122
Operating lease right-of-use assets, net	1,158,776	1,317,830
Intangible assets, net	52,866,192	42,278,211
Prepaid royalties, non-current	339,091	344,321
Deposits	30,000	30,000
Goodwill	7,190,656
Total non-current assets	61,597,532	43,977,484
Total assets	65,999,350	47,083,561
Current
Accounts payable and accrued expenses	1,596,147	478,103
Note payable	127,798
Due to related parties	1,132,634
Operating lease obligations	277,142	243,292
Total current liabilities	3,133,721	721,395
Non-current
Operating lease obligations, net of current portion	881,634	1,074,538
Notes payable, net of current portion	469,252
Convertible notes	26,065
Derivative liabilities	2,485,346
Contingent liabilities	11,313,000
Total non-current liabilities	15,175,297	1,074,538
Total liabilities	18,309,018	1,795,933
Commitments and contingencies (Note 9)
Stockholders’ equity:
Preferred stock, $0.001 par value, 25,000,000 shares authorized, no shares issued and outstanding as of December 31, 2021 and 2020
Common stock, par value $0.001, 75,000,000 shares authorized, issued and outstanding shares - 40,528,188 and 35,928,188 at December 31, 2021 and 2020 respectively	40,528	35,928
Additional paid-in capital	95,473,367	82,077,334
Accumulated deficit	(47,823,563)	(36,825,634)
Total stockholders’ equity	47,690,332	45,287,628
Total liabilities and stockholders’ equity	$ 65,999,350	$ 47,083,561

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	75,000,000	75,000,000
Common stock, shares issued	40,528,188	35,928,188
Common stock, shares outstanding	40,528,188	35,928,188

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Revenue	$ 210,279	$ 197,136
Operating expenses:
Direct costs of revenue	80,354	58,292
Professional fees (includes related party amounts of $410,400, and $180,000, respectively)	2,269,756	1,153,731
Salary expenses	2,887,309	915,210
Research and development	1,681,899	687,734
Stock-based compensation	898,444	1,833,292
Depreciation and amortization	43,871	591,458
Other general and administrative expenses	1,170,029	757,022
Total operating expenses	9,031,662	5,996,739
Total operating loss	(8,821,383)	(5,799,603)
Other expense
Interest and accretion expenses	(126,024)	(45,450)
Change in fair value of contingent liabilities	(1,387,000)
Loss on debt extinguishment	(663,522)
Total other expense	(2,176,546)	(45,450)
Net loss	$ (10,997,929)	$ (5,845,053)
Loss per share – basic and diluted	$ (0.31)	$ (0.22)
Weighted average number of shares of common stock outstanding – basic and diluted	36,041,613	26,373,982

Consolidated Statements of Op_2

Consolidated Statements of Operations (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Professional fees related paty	$ 2,269,756	$ 1,153,731
Related Party [Member]
Defined Benefit Plan Disclosure [Line Items]
Professional fees related paty	$ 410,400	$ 180,000

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2019	$ 19,859	$ 59,303,594	$ (30,980,581)	$ 28,342,872
Beginning balance, shares at Dec. 31, 2019	19,858,939
Common shares issued in lieu of payables	$ 254	261,199		261,453
Common shares issued in lieu of payables, shares	254,057
Common stock issued for services	$ 215	237,285		237,500
Common stock issued for services, shares	215,000
Sale of common stock	$ 5,600	6,269,564		6,275,164
Sale of common stock, shares	5,600,192
Issuance of common stock for acquisition	$ 10,000	12,490,000		12,500,000
Issuance of common stock for acquisition, shares	10,000,000
Issuance of warrants for acquisition		1,932,300		1,932,300
Issuance of warrants for services		253,749		253,749
Stock-based compensation expense		1,329,643		1,329,643
Net loss			(5,845,053)	(5,845,053)
Ending balance, value at Dec. 31, 2020	$ 35,928	82,077,334	(36,825,634)	45,287,628
Ending balance, shares at Dec. 31, 2020	35,928,188
Warrants issued for acquisition		(732,300)		(732,300)
Warrants issued		5,493,821		5,493,821
Issuance of common stock for acquisition	$ 4,600	7,769,400		7,774,000
Issuance of common stock for acquisition, shares	4,600,000
Issuance of warrants for services				368,287
Stock-based compensation expense		865,112		865,112
Net loss			(10,997,929)	(10,997,929)
Ending balance, value at Dec. 31, 2021	$ 40,528	$ 95,473,367	$ (47,823,563)	$ 47,690,332
Ending balance, shares at Dec. 31, 2021	40,528,188

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net loss	$ (10,997,929)	$ (5,845,053)
Adjustments to reconcile net loss to net cash used in operations:
Depreciation and amortization	43,871	591,459
Stock-based compensation	865,112	1,329,643
Stock-based compensation - restricted common stock	33,332
Interest and accretion on convertible notes	126,024
Issuance of common stock for services		237,500
Issuance of warrants  for services	368,287	253,749
Change in fair value of contingent liabilities	1,387,000
Loss on debt extinguishment	663,522
Change in operating assets and liabilities:
Accounts receivable	36,298	(40,585)
Prepaid expense	(184,112)	307,983
Inventory	33,987	127,129
Deposits		(30,000)
Accounts payable and accrued expenses	968,788	(155,661)
Due to related parties	868,725
Net cash used in operating activities	(5,787,095)	(3,223,836)
Cash flows used in investing activities:
Purchase of intangible assets		(148,656)
Net cash used in investing activities		(148,656)
Cash flows from financing activities:
Proceeds from promissory notes	263,907
Proceeds from financing, net of issuance costs	6,692,765
Shares issued for cash, net of offering costs		6,275,164
Net cash provided by financing activities	6,956,672	6,275,164
Net change in cash	1,169,577	2,902,672
Cash at beginning of year	2,902,762	90
Cash at end of year	4,072,339	2,902,762
Supplemental disclosure of cash flow information:
Cash paid for interest		45,449
Cash paid for taxes
Non-cash investing and financing activities:
Derivative liabilities and debt discount issued in connection with convertible notes	2,485,346
Warrants and debt discount issued in connection with convertible notes	5,125,534
Contingent liabilities	9,926,000
Issuance of common stock in lieu of payables		261,453
Issuance of common stock in connection with business combination	7,774,000	12,500,000
Notes payable assumed in connection with business combination	468,137
Issuance of warrants in connection with business combination		1,932,300
Initial adoption of ROU asset and lease liability		$ 1,317,830

Organization, Basis of Presenta

Organization, Basis of Presentation and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Organization, Basis of Presentation and Summary of Significant Accounting Policies	1. Organization, Basis of Presentation and Summary of Significant Accounting Policies Organization Maryzime, Inc. (the “Company” or “Marizyme”) is a Nevada corporation originally incorporated on March 20, 2007, under the name SWAV Enterprises, Ltd. On September 6, 2010, the Company name was changed to GBS Enterprises Inc. and from 2010 to September 2018 the Company was in the software products and advisory services business for email and instant messaging applications. The Company divested that business between December 2016 and September 2018 and focused on the acquisition of life science technologies. On March 21, 2018, the Company’s name was changed to Marizyme, Inc., to reflect the new life sciences focus. Marizyme’s common stock is currently quoted on the OTC Markets’ QB tier under the symbol “MRZM”. Basis of Presentation and Principles of Consolidation The Company’s consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The accompanying consolidated financial statements include the consolidated accounts of the Company and its wholly owned subsidiaries, Somahlution, Inc. (“Somahlution”), Somaceutica, Inc. (“Somaceutica”), Marizyme Sciences, Inc. (“Marizyme Sciences”), and My Health Logic, Inc. (“My Health Logic”). All intercompany transactions have been eliminated on consolidation. Going Concern The Company’s consolidated financial statements are prepared using principals generally accepted in the United States of America applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, the Company does not have an established source of revenues sufficient to cover its operating costs and to allow it to continue as a going concern. The Company, since its inception, has incurred recurring operating losses and negative cash flows from operations and has an accumulated deficit of $ 47,823,563 at December 31, 2021. Additionally, the Company has working capital of $ 1,268,097 and $ 4,072,339 of cash on hand, which may not be sufficient to fund operations for the next twelve months. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Under the going concern assumption, an entity is ordinarily viewed as continuing its business for the foreseeable future with neither the intention or necessity of liquidation, ceasing trading, or seeking protection from creditors pursuant to the laws and regulations. Accordingly, assets and liabilities are recorded on the basis that the entity will be able to realize its assets and discharge its liabilities in the normal course of business. The ability of the Company to continue as a going concern is dependent upon its ability to continue to successfully develop its intangible assets, receive an approval from the U.S. Federal and Drug Administration to extend the selling of the products into the U.S. market which will allow the Company to attain profitable operations. During the next twelve months from the date the consolidated financial statements were issued, the Company’s foreseeable cash requirements will relate to continuous operations of its business, maintaining its good standing and making the required filing with the SEC, and the payment of expenses associated with its product development. The Company may experience a cash shortfall and be required to raise additional capital. Management intends to raise additional funds by way of a private or public offering. Subsequent to the year ended December 31, 2021, on February 14, 2021, Marizyme completed a preliminary prospectus with intention to raise up to $ 17,250,000 The consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. Use of Estimates The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make use of certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reported periods. The Company bases its estimates on historical experience and on various other assumptions that management believes are reasonable under the circumstances, the results of which form the basis for making judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. Significant estimates are related to the allocation of the purchase price in a business combination to the underlying assets and liabilities, recoverability of long-term assets including intangible assets and goodwill, amortization expense, valuation of warrants, stock-based compensation, derivative liabilities, contingent liabilities, and deferred tax valuations. Fair Value Measurements The Company uses the fair value hierarchy to measure the value of its financial instruments. The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair value that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources, while unobservable inputs reflect a reporting entity’s pricing based upon its own market assumptions. The basis for fair value measurements for each level within the hierarchy is described below: ● Level 1 – Quoted prices for identical assets or liabilities in active markets. ● Level 2 – Quoted prices for identical or similar assets and liabilities in markets that are not active; or other model-derived valuations whose inputs are directly or indirectly observable or whose significant value drivers are observable. ● Level 3 – Valuations derived from valuation techniques in which one or more significant inputs to the valuation model are unobservable and for which assumptions are used based on management estimates. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value. The fair value of lease obligations is determined using discounted cash flows based on the expected amounts and timing of the cash flows discounted using a market rate of interest adjusted for appropriate credit risk. The contingent liabilities assumed on the acquisition of Somah (Note 2) consist of present values of royalty payments, performance warrants and pediatric voucher warrants, future rare pediatric voucher sales, and liquidation preference. Management measured these contingencies in accordance with Level 3 of the fair value hierarchy. i. The performance warrants and pediatric vouchers warrants liabilities were valued using a Monte Carlo simulation model utilizing the following weighted average assumptions: risk free rate of 1.19 69.62 0 6.21 417,000 4,352,000 ii. The present value of royalty payments was measured using the scenario-based methodology. In assessing the value attributed to the royalty payments, the estimated future cash flows were discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the revenue from net sales of the product. The cash flows derived from the Company’s fifteen-year strategic plan are based on managements’ expectations of market growth, industry reports and trends, and past performances. These projections are inherently uncertain due to the evolving impact of the COVID-19 pandemic. The discounted cash flow model included projections surrounding revenue, discount rates, and growth rates. The discount rates used to calculate the present value of royalty payments reflect specific risks of the Company and market conditions and the mid-range was estimated at 20.6 1,802,000 3,988,000 iii. Rare pediatric voucher sales liability was valued based on the scenario-based methodology where the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset – 20.6 2,000 1,150,000 iv. The present value of liquidation preference liability, included in the contingent consideration, was determined using the Black-Scholes option pricing method and represents the fair value of the maximum payment amount according to the Agreement. The following assumptions were used in the Black-Scholes option pricing model: risk free rate of 0.21 78.93 0 5 years No 1,823,000 The derivative liabilities consisted of optional and automatic conversion features and the share redemption feature attached to the convertible notes, issued pursuant to the Unit Purchase Agreement (Note 6). The Company has no financial assets measured at fair value on a recurring basis. None of the Company’s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented. Marizyme measures the following financial instruments at fair value on a recurring basis. At December 31, 2021 and 2020, the fair values of these financial instruments were as follows: Schedule Of Fair Values of Financial Instruments December 31, 2021 Level 1 Level 2 Level 3 December 31, 2020 Fair Value Hierarchy December 31, 2021 Level 1 Level 2 Level 3 December 31, 2020 Liabilities Derivative liabilities $ - $ - $ 2,485,346 $ - Contingent liabilities - - 11,313,000 - Total $ - $ - $ 13,798,346 $ - The following table provides a roll forward of all liabilities measured at fair value using Level 3 significant unobservable inputs: Schedule of Liabilities Fair Value Measured Derivative and Contingent Liabilities Balance at December 31, 2020 - Derivative liabilities $ 391,648 Extinguishment of debt obligations (391,648 ) Derivative liabilities - amended Unit Purchase Agreement (Note 6) 2,485,346 Initial valuation of contingent liabilities assumed on Somah acquisition 1 9,926,000 Change in fair value 1,387,000 Balance at December 31, 2021 $ 13,798,346 1 Measured as at Somah acquisition date of July 31, 2020, see Note 2. Cash Cash include cash in readily available checking accounts. Concentrations of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. Inventory Inventory consisted of primarily finished goods and is valued at the lower of cost and net realizable value. Cost is determined using the FIFO method. The Company decreases the value of inventory for estimated obsolescence equal to the difference between the cost of inventory and the estimated market value, based upon an aging analysis of the inventory on hand, specifically known inventory-related risks, and assumptions about future demand and market conditions. The Company has determined that no inventory reserve was necessary as of December 31, 2021 and 2020. Accounts Receivable Trade receivables are amounts due from customers for goods sold in the ordinary course of business. Accounts receivable are non-interest bearing and are due for settlement in full within 30 days. Trade receivables are shown net of allowance for bad or doubtful debts. Allowance for Doubtful Accounts The Company establishes an allowance for doubtful accounts to ensure trade and other receivables are not overstated due to non-collectability. The Company’s allowance is based on a variety of factors, including age of the receivable, significant one-time events, historical experience, and other risk considerations. The Company did not have an allowance at December 31, 2021 or 2020. The Company did not record any bad debt expense in each of the years ended December 31, 2021 and 2020. Property, Plant, and Equipment, Net Property, plant and equipment are recorded at cost, less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the useful life of the asset. Machinery, computer equipment and related software are depreciated over five to seven years. Furniture and fixtures are depreciated over four seven years Intangible Assets and Goodwill Intangible assets are recorded at cost less accumulated amortization and accumulated impairment losses. Intangible assets acquired as a result of an acquisition or in a business combination are measured at fair value at the acquisition date. The useful lives of intangible assets are assessed as either finite or indefinite. Intangible assets with finite lives are amortized over the estimated useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The estimated useful life and amortization method are reviewed at the end of each reporting period, with the effect of any changes in estimates being accounted for on a prospective basis. Goodwill represents the excess of the purchase price paid for the acquisition of subsidiaries over the fair value of the net assets acquired. Following the initial recognition, goodwill is measured at cost less any accumulated impairment losses. In-Process Research and Development The Company evaluates whether acquired intangible assets are a business under applicable accounting standards. Additionally, the Company evaluates whether the acquired assets have a future alternative use. Intangible assets that do not have future alternative use are considered acquired in-process research and development (“IPR&D”). When the acquired in-process research and development assets are not part of a business combination, the value of the consideration paid is expensed on the acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred. These IPR&D assets are reviewed for impairment annually, or sooner if events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable, and upon establishment of technological feasibility or regulatory approval. An impairment loss, if any, is calculated by comparing the fair value of the asset to its carrying value. If the asset’s carrying value exceeds its fair value, an impairment loss is recorded for the difference and its carrying value is reduced accordingly. Similar to the impairment test for goodwill, the Company may perform a qualitative approach for testing indefinite-lived intangible assets for impairment. The Company used the qualitative approach and concluded that it was more-likely-than-not that its indefinite-lived assets were not impaired during the years ended December 31, 2021 and 2020. Impairment of Long-Lived Assets The Company reviews long-lived assets, including property, plant and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount. The impairment loss, if recognized, would be based on the excess of the carrying value of the impaired asset over its respective fair value. No impairment losses have been recorded through December 31, 2021 and 2020. Leases At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company records the associated lease liability and corresponding right-of-use asset upon commencement of the lease using the implicit rate or a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. The Company additionally evaluates leases at their inception to determine if they are to be accounted for as an operating lease or a finance lease. A lease is accounted for as a finance lease if it meets one of the following five criteria: the lease has a purchase option that is reasonably certain of being exercised, the present value of the future cash flows is substantially all of the fair market value of the underlying asset, the lease term is for a significant portion of the remaining economic life of the underlying asset, the title to the underlying asset transfers at the end of the lease term, or if the underlying asset is of such a specialized nature that it is expected to have no alternative uses to the lessor at the end of the term. Leases that do not meet the finance lease criteria are accounted for as an operating lease. Operating lease assets represent a right to use an underlying asset for the lease term and operating lease liabilities represent an obligation to make lease payments arising from the lease. Operating lease liabilities with a term greater than one year and their corresponding right-of-use assets are recognized on the balance sheet at the commencement date of the lease based on the present value of lease payments over the expected lease term. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. As the Company’s leases do not typically provide an implicit rate, the Company utilizes the appropriate incremental borrowing rate, determined as the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and in a similar economic environment. Lease cost is recognized on a straight-line basis over the lease term and variable lease payments are recognized as operating expenses in the period in which the obligation for those payments is incurred. Variable lease payments primarily include common area maintenance, utilities, real estate taxes, insurance, and other operating costs that are passed on from the lessor in proportion to the space leased by the Company. The Company has elected the practical expedient to not separate between lease and non-lease components. Revenue Recognition Pursuant to Topic 606, the Company recognizes revenue to depict the transfer of promised goods or services to a customer in an amount that reflects the consideration to which the entity expects to be intitled in exchange for those goods or services. To achieve this core principle, Topic 606 outlines a five-step process for recognizing revenue from customer contracts that includes i) identification of the contract with a customer, ii) identification of the performance obligations in the contract, iii) determining the transaction price, iv) allocating the transaction price to the separate performance obligations in the contract, and v) recognizing revenue associated with performance obligations as they are satisfied. At contract inception, the Company assesses the goods or services promised within each contract and assess whether each promised good or service is distinct and determine those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied. We have identified one performance obligation which is related to our DuraGraft product sales. For our Distribution Partner channel, we recognize revenue for product sales at the time of delivery of the product to our Distribution Partner (customer). As our products have an expiration date, if a product expires, we will replace the product at no charge. There were no significant judgements made in applying this topic. Direct Cost of Revenue Cost of sales includes the actual cost of merchandise sold, and the cost of transportation of merchandise from our third-party vendor to our distributer. Research and Development Expenses and Accruals All research and development costs are expensed in the period incurred and consist primarily of salaries, payroll taxes, and employee benefits, those individuals involved in research and development efforts, external research and development costs incurred under agreements with contract research organizations and consultants to conduct and support the Company’s ongoing clinical trials of Duragraft, and costs related to manufacturing Duragraft for clinical trials. The Company has entered into various research and development contracts with various organizations and other companies. Payments of these activities are based on the terms of the individual agreements which matches to the pattern of costs incurred. Payments made in advances are reflected in the accompanying balance sheets as prepaid expenses. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates. Stock-Based Compensation Share-based compensation expense for employees and directors is recognized in the Consolidated Statement of Operations based on estimated amounts, including the grant date fair value and the expected service period. For stock options, we estimate the grant date fair value using a Black-Scholes valuation model, which requires the use of multiple subjective inputs including estimated future volatility, expected forfeitures and the expected term of the awards. We estimate the expected future volatility based on the stock’s historical price volatility. The stock’s future volatility may differ from the estimated volatility at the grant date. For restricted stock unit (“RSU”) equity awards, we estimate the grant date fair value using our closing stock price on the date of grant. We recognize the effect of forfeitures in compensation expense when the forfeitures occur. The estimated forfeiture rates may differ from actual forfeiture rates which would affect the amount of expense recognized during the period. We recognize the value of the awards over the awards’ requisite service or performance periods. The requisite service period is generally the time over which our share-based awards vest. Income Taxes The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the statement of operations in the period that includes the enactment date. The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. The Company records uncertain tax positions on the basis of a two-step process whereby (i) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability. There were no interest and penalties as of December 31, 2021 and 2020. Segment Reporting Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as one Net Loss Per Share Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Dilutive common stock equivalents are comprised of unvested common stock, options and warrants. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities (warrants, stock options, and common shares subject to repurchase) would be antidilutive. Comparative Information To conform with the current year’s financial statement presentation, the Company reclassified certain professional fees, salaries, and rent expenses related to research and development activities for the year ended December 31, 2020 into research and development expenses line item on the Consolidated Statements of Operations. Such reclassifications were not considered material and did not have any effect on the Company’s net loss for the year ended December 31, 2020. Recently Adopted Accounting Standards In December 2019, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes Recently Issued Accounting Pronouncements The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board or other standard setting bodies on the Company’s consolidated financial statements as well as material updates to previous assessments. There were no new material accounting standards issued or adopted in year of 2021 that impacted the Company.

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2021
Business Combination and Asset Acquisition [Abstract]
Acquisitions	2. Acquisitions DuraGraft® On December 15, 2019, the Company entered into a contingent asset purchase agreement (the “Agreement”), as amended on March 31, 2020 and May 29, 2020, with Somahlution, LLC, Somahlution, Inc., and Somaceutica, LLC, companies duly organized under the laws of Delaware (collectively, “Somah” or “Seller”) to acquire all of the assets and none of the liabilities of Somah (the “Acquisition”), including DuraGraft®, a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, and other related properties. On July 31, 2020, the Company and Somah entered into Amendment No. 3 to the Agreement and the Agreement was finalized. Pursuant to the terms of this amendment, it was agreed that, as part of the Acquisition, the Company would acquire the outstanding capital stock of Somahlution, Inc., held by Somahlution, LLC, rather than the assets of Somahlution, Inc. This change to the Agreement was made to accommodate the European Union (“EU”) requirements with respect to the future manufacturing under Somahlution, Inc. of CE marked products for sale in the EU. In Amendment No. 3, the Company agreed to assume certain payables of Somah related to clinical and medical expenses. It was agreed that the payments on the assumed debts would be recorded as a prepaid royalty against future royalties. As of December 31, 2021 and 2020, prepaid royalties were $ 339,091 344,321 Pursuant to the Agreement and in consideration of the outstanding capital stock of Somahlution, Inc., the Company agreed to issue to Somah: ● 10,000,000 ● Warrants to purchase 3,000,000 5.00 five years ● The Company, on a pro rata basis, shall grant the Seller the following contingent consideration upon receiving the FDA final approval and insurance reimbursement approval on the product: ○ Grant of performance warrants for 4,000,000 ○ Royalties to be paid on all net sales of the product acquired from Somah of 6 50 5 50 4 50 200 2 200 ○ Payment of 10 ○ Grant of rare pediatric voucher warrants to purchase an aggregate of 250,000 ○ Liquidation preference, up to a maximum of $ 20 15 On July 30, 2020, the Company completed the acquisition of Somah (the “Somah Transaction”). The acquisition of Somah provides the Company with access to DuraGraft and other related intangible assets, which upon approval by FDA, will further the Company’s continued growth and international-wide product rollout. In accordance with ASC 805-10 the substance of a transaction constitutes a business combination as the business of Somah meets the definition of a business under the standard. Accordingly, the transaction was accounted for in accordance with the acquisition method of accounting, and the assets acquired, and the liabilities assumed have been recorded at their respective estimated fair values as of the acquisition date. The purchase price is based on management’s estimate of fair value of the common shares and warrants issued as well as contingent consideration and liquidation preference given up. The final allocation of the purchase price consideration to the assets acquired and liabilities assumed has been completed and finalized. Details of the carrying amount and the fair value of identifiable assets and liabilities acquired and purchase consideration paid are as follows: Schedule of Preliminary Allocation of Consideration Consideration Common shares $ 12,500,000 Warrants 1,200,000 Contingent consideration 1 9,926,000 Total consideration $ 23,626,000 Fair value of identifiable assets acquired, and liabilities assumed Net working capital $ 30,908 Property, plant, and equipment 9,092 Intangible assets 18,170,000 Goodwill 5,416,000 Total identifiable assets $ 23,626,000 1 During the year ended December 31, 2021, for the purposes of the final allocation of the purchase price consideration, contingent consideration was measured as of the date of Somah acquisition - July 31, 2020 and valued at $ 9,926,000 1,387,000 to $ 11,313,000 (Note 1). The intangible assets acquired include: ● DuraGraft patent, with estimated remaining economic life of 13 years ● “Distribution relationships” intangible asset related to DuraGraft products, with estimated remaining economic life of 10 years ● In-process research and development intangible asset – “Cyto Protectant Life Sciences” with indefinite economic life. Goodwill is attributed to the workforce and profitability of the acquired business and is not deductible for tax purposes. A residual method methodology was used to estimate the fair market value goodwill. A pre-tax discount rate based on weighted average cost of capital of 33.8 Pro-forma revenue, net income, and earnings per share are not presented for this acquisition as they are not material. My Health Logic Inc. On November 1, 2021, Marizyme entered into a definitive arrangement agreement with Health Logic Interactive Inc. (“HLII”) pursuant to which the Company will acquire all of the issued and outstanding common shares of My Health Logic Inc. (“My Health Logic” or “MHL”), a wholly owned subsidiary of HLII, in exchange for common shares of Marizyme (the “Marizyme Shares”). Marizyme is dedicated to the acceleration, development and commercialization of medical technologies that promote patient health, therefore a strategic decision was made during the year ended December 31, 2021 to acquire My Health Logic, which have provided Marizyme with access to MHL’s lab-on-chip technology platform and its patient-centric, digital point-of-care diagnostic device, MATLOC 1; and allowed for further growth and development of Marizyme’s portfolio of medical products. On December 22, 2021, Marizyme received the necessary regulatory, court and stock exchange approval to complete the acquisition of MHL resulting in a total of 4,600,000 230,000 11.35 40,528,188 In accordance with ASC 805-10 the substance of a transaction constitutes a business combination as the business of My Health Logic Inc. meets the definition of a business under the standard. Accordingly, the transaction was accounted for in accordance with the acquisition method of accounting, and the assets acquired, and the liabilities assumed have been recorded at their respective estimated fair values as of the acquisition date. The purchase price is based on management’s estimate of fair value of the common shares issued. According to ASC 805 the acquirer has a year from the date of acquisition to recognize measurement period adjustments. While Marizyme doesn’t expect the carrying amount and the fair value of identifiable assets and liabilities acquired, provided below, to change, the estimates surrounding the useful life of intangible assets acquired may differ from the initial values determined. The change in useful life of the intangible assets will not have a material impact on the net loss for the year ended December 31, 2021. Additionally, The Company is in the process of finalizing the tax basis related to these intangible assets which is not final as of December 31, 2021. Details of the carrying amount and the fair value of identifiable assets and liabilities acquired and purchase consideration paid are as follows: Schedule of Assets and Liabilities Acquired and Purchase Consideration Consideration given up Common shares $ 7,774,000 Total consideration given up $ 7,774,000 Fair value of identifiable assets acquired, and liabilities assumed Net working deficit $ (613,156 ) Property, plant, and equipment 12,500 Intangible assets 6,600,000 Goodwill 1,774,656 Total identifiable assets $ 7,774,000 As a result of the My Health Logic acquisition, we acquired its lab-on-chip technology platform, its patient-centric, digital point-of-care diagnostic device - MATLOC 1 as well as patents rights and trademarks relating to it. In addition, we acquired ownership rights to MATLOC patents issued in the European Union, Canada, and the United States. The intangible assets acquired include: ● Trade name, with estimated remaining economic life of 14 years ● Software, which enables customers to track and update their test results, with economic life of 15 years ● Biotechnology intangible assets related to lab-on-chip technology, with estimated remaining economic life of 17 years As part of the acquisition, Marizyme assumed an aggregate of $ 468,137 9 August 12, 2022 1,115 Nil Goodwill is attributed to the workforce and profitability of the acquired business and is not deductible for tax purposes. A residual method methodology was used to estimate the fair market value goodwill. A pre-tax discount rate based on weighted average cost of capital of 37.5 Pro-forma revenue, net income, and earnings per share are not presented for this acquisition as they are not material.

Leases

Leases	12 Months Ended
	Dec. 31, 2021
Leases
Leases	3. Leases On December 11, 2020, the Company entered into a 5.5 10,817 2.5 12,000 4.42 The assets and liabilities from the lease were recognized at the lease commencement date based on the present value of remaining lease payments over the lease term using the discount rate of 3.95 %, which is the average commercial interest available to the Company at the time. The following table summarizes supplemental balance sheet information related to the operating lease as of December 31, 2021: Schedule of Right-of-Use Asset and Related Lease Liabilities December 31, December 31, Right-of-use asset $ 1,158,776 $ 1,317,830 Operating lease liabilities, current $ 277,142 $ 243,292 Operating lease liabilities, non-current 881,634 1,074,538 Total operating lease liabilities $ 1,158,776 $ 1,317,830 As at December 31, 2021, the maturities of the lease liabilities for the periods ended December 31 were as follows: Schedule of Maturities of the Lease Liabilities 2022 $ 277,142 2023 277,142 2024 277,142 2025 277,142 Thereafter 130,950 Total lease payments 1,239,518 Less: Present value discount (80,742 ) Total $ 1,158,776

Intangible Assets and Goodwill

Intangible Assets and Goodwill	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	4. Intangible Assets and Goodwill Krillase As part of the asset acquisition of ACB Holding AB, Reg. No. 559119-5762, completed on September 12, 2018, Marizyme acquired all rights, titles, and interest in the Krillase technology, a group of intangible assets worth $ 28,600,000 . Krillase is a naturally occurring enzyme that acts to break protein bonds and has applications in wound debridement, wound healing, dental care and thrombosis. The useful lives of the intangible assets are based on the life of the patent and related technology. The patents and related technology for Krillase have not been amortized since the acquisition, as they have not yet been put into operations. The Company used the qualitative approach and concluded that it was more-likely-than-not that its Krillase assets were not impaired during the years ended December 31, 2021 and 2020. DuraGraft As part of Somah acquisition (Note 2), Marizyme purchased $ 18,170,000 of intangible assets related to the DuraGraft® technology. No My Health Logic As part of My Health Logic acquisition (Note 2), Marizyme purchased MHL’s lab-on-chip technology platform and its patient-centric, digital point-of-care diagnostic device, MATLOC, fair valued at an aggregate amount of $ 6,600,000 Schedule of Intangible Assets Amortization Expense Intangible Assets December 31, 2021 December 31, 2020 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Krillase intangible assets $ 28,600,000 $ - $ 28,600,000 $ 28,600,000 $ - $ 28,600,000 Patents in process 122,745 - 122,745 119,971 - 119,971 DuraGraft patent 5,256,000 (572,768 ) 4,683,232 14,147,729 (589,489 ) 13,558,240 Duragraft - Distributor relationship 308,000 (43,633 ) 264,367 - - - Duragraft IPR&D - Cyto Protectant Life Sciences 12,606,000 - 12,606,000 - - - My Health Logic - Trade name 450,000 (804 ) 449,196 - - - My Health Logic - Biotechnology 4,600,000 (6,765 ) 4,593,235 - - - My Health Logic - Software 1,550,000 (2,583 ) 1,547,417 - - - Total intangible assets $ 53,492,745 $ (626,553 ) $ 52,866,192 $ 42,867,700 $ (589,489 ) $ 42,278,211 Schedule of Goodwill Goodwill DuraGraft My Health Logic Total Balance, December 31, 2020 $ - $ - $ - Additions on acquisitions 5,416,000 1,774,656 7,190,656 Impairment - - - Balance, December 31, 2021 $ 5,416,000 $ 1,774,656 $ 7,190,656 The following changes to the Company’s intangible assets had taken place in the periods indicated: Schedule of Intangible Assets Balance, December 31, 2019 $ 28,613,000 Acquired in asset purchase agreement 14,147,729 Additions 106,971 Amortization expense (589,489 ) Balance, December 31, 2020 $ 42,278,211 Acquired in Somah Transaction 1 4,022,271 Acquired in MHL Transaction 6,600,000 Additions 2,775 Amortization expense 1 (37,065 ) Balance, December 31, 2021 $ 52,866,192 1 To account for Somah Transaction measurement period adjustments, the Company restated the Quarterly Report on Form 10-Q for the three and six month ended June 30, 2021, originally filed on August 23, 2021. As a result of the restatement, the value of DuraGraft intangibles purchased with the Somah Transaction increased by $ 4,022,271 898,026 As the result of the Somah Transaction measurement period adjustments, the Company has recorded amortization expense of $ 37,066 589,489 Future amortizations for Duragraft and My Health Logic intangible assets for the next five years will be $ 841,172 7,331,585

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	12 Months Ended
	Dec. 31, 2021
Payables and Accruals [Abstract]
Accounts Payable and Accrued Expenses	5. Accounts Payable and Accrued Expenses Accounts payable and accrued expenses, summarized by major category, as of December 31, 2021 and 2020 consists of the following: Schedule of Accounts Payable And Accrued Liabilities December 31, 2021 December 31, Trade accounts payable $ 1,465,860 $ 325,830 Accrued expenses 8,215 21,555 Accrued compensation expenses 122,072 130,718 Total accounts payable and accrued expenses $ 1,596,147 $ 478,103

Convertible Promissory Notes an

Convertible Promissory Notes and Warrants	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Convertible Promissory Notes and Warrants	6. Convertible Promissory Notes and Warrants May 2021 Unit Purchase Agreement On May 27, 2021, Marizyme entered into a Unit Purchase Agreement to sell up to 4,000,000 2.50 Each Unit is comprised of (i) a convertible promissory note convertible into common stock of the Company, (ii) a warrant to purchase one share of common stock of the Company (the ‘Class A Warrant’); and (iii) a second warrant to purchase common stock of the Company (the “Class B Warrant”) In May 2021, the Company issued and sold 29,978 2.50 74,945 74,945 29,978 29,978 6,745 In July 2021, the Company issued and sold 440,000 1,100,000 1,100,000 440,000 440,000 September 2021 Amended Unit Purchase Agreement On September 29, 2021, due to a lower common stock price, the Company, with the consent of all Unit holders, amended the May 2021 Unit Agreements. By rescinding their investment, the Unit holders agreed to amend the Unit Purchase Agreement resulted in the following significant changes to the offering: (iv) Decreased the offering price under the Unit Purchase Agreement from $ 2.50 2.25 (v) Decreased the conversion price from $ 2.50 2.25 (vi) Cancelled all Class A Warrants and Class B Warrants and replaced them with Class C Warrants. December 2021 Unit Purchase Agreement On December 21, 2021, the Company entered into a Unit Purchase Agreement (the “December UPA”) to sell up to 9,714,286 1.75 Each Unit is comprised of (i) a convertible promissory note convertible into common stock of the Company at an initial conversion price of $1.75 and, (ii) a warrant to purchase two shares of Common Stock at an initial purchase price of $2.25 per share (the new Class C Warrant) 3,438,572 1.75 6,000,000 December 2021 Exchange Agreements On December 21, 2021, in conjunction with a $ 6.0 (v) Decreased the offering price under the Unit Purchase Agreement from $ 2.25 1.75 (vi) Extended the maturity date of the notes to December 21, 2023 (vii) Decreased the conversion price from $ 2.25 1.75 (viii) Original Class C Warrants were exchanged for New Class C warrants with an exercise price of $ 2.25 200 The Company determined that the terms of the New Securities were substantially different from the Original Securities, and, as such the exchange of the Original Securities for the New Securities was accounted for as an extinguishment of debt on December 21, 2021, and the New Securities accounted for as a new debt issuance. As a result of this substantial modification, the total of 621,087 Units previously issued were replaced with an aggregate of 832,022 pro-rata Units and a loss on debt extinguishment of $ 663,522 was recorded in consolidated statements of operations for the year ended December 31, 2021 (2020 - $ Nil ). The Company determined that the optional and automatic conversion feature and the share redemption feature attached to the convertible notes meet the definition of derivative liabilities and that the detachable warrants issued do not meet the definition of a liability and therefore will be accounted for as an equity instrument. The fair value of the warrants of $ 4,299,649 2,485,346 During the year ended December 31, 2021, the Company recognized interest and accretion expense of $ 116,676 Nil Schedule of Convertible Notes December 31, 2021 December 31, 2020 Convertible notes issued - original securities $ 1,174,945 $ Issuance costs (105,745 ) - Debt discount (964,153 ) - Debt accretion 90,611 - Extinguishment of debt in connection with December 2021 Exchange Agreements (195,658 ) - Convertible notes issued - new securities, outstanding at December 31, 2021 7,456,039 - Issuance costs (671,044 ) Debt discount (6,784,995 ) - Debt accretion 26,065 - Convertible notes, net of debt discount $ 26,065 $ - Convertible Notes Terms The Convertible Notes mature in 24 months from the initial closing date and accrue 10% of simple interest per annum on the outstanding principal amount The Convertible Notes principal and accrued interest can be converted at any time at the option of the holder at a conversion price of $1.75 per share (previously $2.25 per the September 2021 Amendment and originally $2.50 per the May Unit Purchase Agreement) 10,000,000 75 1.75 New Class C Warrants Terms ● Exercise price is the lower of (i) $ 2.25 75 2.25 ● Exercisable for a period of 5 ● Warrant Coverage: 200

Stockholders_ Equity

Stockholders’ Equity	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Stockholders’ Equity	7. Stockholders’ Equity a) Preferred stock The Company is authorized to issue a total number of 25,000,000 0.001 no b) Common stock The Company is authorized to issue a total number of 75,000,000 0.001 As of December 31, 2021 there were 40,528,188 35,928,188 ● On December 22, 2021, the Company issued 4,600,000 During the year end December 31, 2020, the Company issued the following: ● On January 9, 2020, the Company settled trade payables of $ 126,250 125,000 ● On April 6, 2020, the Company settled trade payables of $ 161,600 160,000 ● On April 6, 2020, the Company issued 5,000 ● On April 6, 2020, the Company issued 15,000 15,150 ● On June 8, 2020, the Company settled trade payables of $ 20,200 20,000 ● On July 28, 2020, the Company issued 64,057 59,453 ● On July 28, 2020, the Company issued 20,000 25,000 ● On July 31, 2020, the Company completed the Soma Acquisition (Note 2) whereas 10,000,000 12,500,000 ● On August 3, 2020, the Company completed an initial closing of a private placement pursuant to which the Company sold and issued an aggregate of 4,609,984 1.25 In consideration for services rendered as the placement agent in the private placement, the Company paid Univest Securities LLC cash commissions totaling $460,999, or 8% of the gross proceeds of the private placement closing, a 1% non-accountable expense allowance totaling $57,625, and the $31,250 balance (of a total of $37,500) due to the placement agent in advisory fees five 229,499 1.375 100 ● On September 1, 2020, the Company issued 40,000 ● On September 25, 2020, the Company closed on the second tranche of funding in the gross amount of $ 1,237,760 990,208 1,116,566 ● On October 1, 2020, the Company entered into a consulting agreement which had various compensation requirements, including the issuance of 20,000 1.25 36,364 1.375 c) Options On May 18, 2021, our Board of Directors approved the Marizyme, Inc. Amended and Restated 2021 Stock Incentive Plan (“SIP”). The SIP incorporates stock options issued prior to May 18, 2021. The SIP authorized 5,300,000 options for issuance. As of December 31, 2021, there remains 1,649,057 options available for issuance. During the year ended December 31, 2021, the company granted 1,532,500 1,340,000) Schedule of Share Based Stock Option Valuation Assumptions 2021 2020 Risk-free interest rate 1.09 % 0.93 % Volatility 252.08 % 241.88 % Exercise price $ 1.51 $ 1.37 Dividend yield 0 % 0 % Forfeiture rate 0 % 0 % Expected life (years) 6.38 10.00 The Company recognizes forfeitures as they occur. The summary of option activity for the years ended December 31, 2021 and 2020 was as follows: Schedule of Stock Option Activities Number of Options Weighted Average Exercise Price Weighted Average Contractual Life Total Intrinsic Value Outstanding at December 31, 2019 2,715,000 $ 1.50 9.48 Granted 1,340,000 1.25 Exercised (254,057 ) 1.02 Outstanding at December 31, 2020 3,800,943 $ 1.36 8.82 Granted 1,532,500 1.51 Forfeited (1,682,500 ) 1.36 Outstanding at December 31, 2021 3,650,943 $ 1.24 8.34 $ 1,951,117 Exercisable at December 31, 2021 2,399,371 $ 1.07 7.70 $ 1,685,099 As of December 31, 2021, the Company had the following options issued and outstanding: Schedule of Options Outstanding and Exercisable Exercise Price Number of Options Outstanding Number of Options Exercisable Weighted Average Remaining Contractual Years Intrinsic Value $ 1.01 1,985,943 1,985,943 7.43 $ 1,509,317 1.25 665,000 213,428 9.09 110,983 1.37 200,000 160,000 8.63 64,000 1.75 800,000 40,000 9.84 800 $ 1.24 3,650,943 2,399,371 8.34 $ 1,951,117 d) Restricted Share Units During the year ended December 31, 2021, the Company granted restricted share awards for an aggregate of 350,000 Nil Nil Nil e) Warrants Schedule of Warrants Outstanding Number Weighted Average Price December 30, 2019 113,637 $ 3.00 Issued on Somah acquisition 3,000,000 5.00 Issued 280,014 1.38 December 30, 2020 3,393,651 $ 2.13 Issued pursuant to Unit Purchase Agreement 8,521,187 2.25 Issued 230,000 1.39 December 31, 2021 12,144,838 $ 2.20 During the year ended December 31, 2021, the Company issued the following: Unit Purchase Agreements Warrants Pursuant to the May Unit Purchase Agreement (Note 6) the Company issued: (i) Class A Warrants for the purchase an aggregate of 469,978 3.13 five years 469,978 5.00 five years On September 29, 2021, pursuant to the September 2021 Amended Unit Purchase Agreement, all Class A and Class B warrants were replaced with an aggregate of 1,045,549 2.25 five years On December 2, 2021, the Company issued additional 197,777 Class C warrants with the terms and conditions stipulated in the September 2021 Amended Unit Purchase Agreement. On December 21, 2021, pursuant to the December 2021 Exchange Agreements (Note 6) all previously issued Original Class C warrants were replaced with an aggregate of 1,664,044 2.25 On December 21, 2021, pursuant to the December 2021 Unit Purchase Agreement the Company issued additional 6,857,143 2.25 five years The detachable warrants issued were accounted for as an equity instrument and were ascribed an aggregate fair market value of $ 4,447,982 Other Warrants 230,000 shares of common stock for a settlement and services rendered. The warrants issued have an average strike price of $ 1.39 per share and an average term of 4.74 years, were fair valued at $ 368,287 During the year end December 31, 2020, the Company issued the following: On July 31, 2020, the Company completed the Somah Acquisition (Note 2) whereas 10,000,000 3,000,000 5.00 five years 0.40 1,200,000 On September 25, 2020, the Company issued two warrants for services. The warrants were to purchase 168,008 112,006 1.375 five years 0.9062 152,249 101,500 253,749 f) Stock-based compensation During the year ended December 31, 2021, the Company recorded $ 865,111 in non-cash share-based compensation (2020 - $ 1,833,292 ). Additionally, the Company recognized $ 33,333 of stock-based compensation on restricted common stock in the year ended December 31, 2021.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	8. Related Party Transactions As at December 31, 2021, the Company owed an aggregate of $ 1,132,634 Nil i. During the year ended December 31, 2021, the Company entered into a promissory note agreement with Brad Richmond, a related party and former acting Vice President of Finance, for the total proceeds of $ 168,907 Nil 368,500 168,907 Nil ii. During the year ended December 31, 2021, the Company entered into a promissory note agreement with Frank Maresca, a related party and shareholder of the Company, for the total proceeds of $ 95,000 Nil 360,000 180,000 198,841 871,371 Nil iii. The Company received consulting services from other shareholders, consultants, and related parties of the Company, and pursuant to the various agreements incurred an aggregate $ 50,400 Nil 41,956 92,356 Additionally, as part of the Somah transaction in 2020 (Note 2), the Company recorded a prepaid royalty to the shareholders of Somahlution. The primary beneficial owner is Dr. Vithal Dhaduk, a director and significant shareholder of the Company. As at December 31, 2021, the company had $ 339,091 in prepaid royalties (2020 - $ 344,321 ) which had been classified as non-current in the consolidation balance sheets.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	9. Commitments and Contingencies Legal Matters Dr. Vithal D. Dhaduk (“Dhaduk”), former Interim CEO of Marizyme and a co-founder of Somahlution, LLC, was the subject of a complaint filed in the United States District Court, Middle District of Pennsylvania, Civil Action No. 3:17 cv 02243 in December 2017 by Mukeshkkumar B. Patel (“Patel”), a former business partner of Dhaduk, which complaint made claims of breach of contract, promissory estoppel and unjust enrichment regarding a Memorandum of Understanding, dated July 16, 2015, between Patel and Dhaduk (“MOU”). The MOU provided that Dhaduk would pay Patel $ 9,450,000 On August 19, 2021, Dr. Neil Campbell, former President, Chief Executive Officer and director of the Company, and Bruce Harmon, former Chief Financial Officer and Secretary of the Company, each filed a Complaint and Demand for Jury Trial against the Company and Insperity Peo Services, L.P., a Delaware limited partnership (“Insperity”), a joint employer of Dr. Campbell and Mr. Harmon with the Company under a Client Service Agreement, dated November 30, 2020 (collectively, the “Campbell/Harmon Complaints”). Both Campbell/Harmon Complaints allege that the Company and Insperity violated Section 448.105 of the Florida Private Whistleblower Act as a result of the constructive terminations of Dr. Campbell and Mr. Harmon after the occurrence of violations federal and state law, including federal securities law, at the Company that exposed Dr. Campbell and Mr. Harmon to civil and criminal forms of liability and that the Company was not addressing to their satisfaction. Both Campbell/Harmon Complaints demand approximately $ 30,000 50,000 Contingencies a. On July 13, 2019, the Company signed a consulting agreement, whereby the individual will receive: ● $ 30,000 ● Option to purchase 250,000 1.50 ● Royalties based on sales of Krillase assets, equal to 10 b. As part of the DuraGraft Acquisition, completed on July 31, 2020 (Note 2), the Company entered into the Agreement with Somah stockholders, whereby Marizyme is legally obligated to pay royalties on all net sales for Somahlution, Inc. The royalties associated with the Agreement are calculated as follows: Royalties on U.S. sales equal to: ● 5 ● 4 ● 2 Royalties on sales outside of the U.S.: ● 6 ● 4 ● 2 The royalties are in perpetuity. As at December 31, 2021, the Company had not earned any revenues from Krillase and did not have any sales of the DuraGraft products in U.S., therefore no royalties have been accrued or paid in the year. Upon receiving FDA approval for the Duragraft product, the Company will: ● Issue performance warrants with a strike price determined based on the average of the closing prices of the Company’s common stock for the 30 calendar days following the date of the public announcement of the FDA approval; and ● Upon liquidation of all or substantially all of the assets relating to DuraGraft, the Company will pay 15 20 c. The Company has entered into arrangements for office and laboratories spaces. As at December 31, 2021, minimum lease payments in relation to lease commitments are payable as described in Note 3. Risks and Uncertainties Starting in late 2019, a novel strain of the coronavirus, or COVID-19, began to rapidly spread around the world and every state in the United States. At this time, there continues to be significant volatility and uncertainty relating to the full extent to which the COVID-19 pandemic and the various responses to it will impact our business, operations and financial results. Most states and cities have at various times instituted quarantines, restrictions on travel, “stay at home” rules, social distancing measures and restrictions on the types of businesses that could continue to operate, as well as guidance in response to the pandemic and the need to contain it. As a result, the COVID-19 pandemic may affect the operations of the FDA and other health authorities, including such authorities in Europe, which could result in delays of reviews and approvals. While there have been no specific notices of delay from federal or foreign government authorities, potential interruptions, delays, or changes to the operations of the FDA, or of any foreign authority with which we might interact, might impact the approval of any applications we plan and will need to file in the future. In addition, we are dependent upon certain contract manufacturers and suppliers and their ability to reliably and efficiently fulfill our orders is critical to our business success. The COVID-19 pandemic has impacted and may continue to impact certain of our manufacturers and suppliers. As a result, we have faced and may continue to face delays or difficulty sourcing certain products, which could negatively affect our business and financial results. The spread of COVID-19 has also adversely impacted global economic activity and has contributed to significant volatility and negative pressure in financial markets. The pandemic has resulted, and may continue to result, in a significant disruption of global financial markets, which may reduce our ability to access capital in the future, which could negatively affect our liquidity. If the COVID-19 pandemic does not continue to slow and the spread of COVID-19 is not contained, our business operations, including those of contract manufacturers, could be further delayed or interrupted. The duration of any business disruption cannot be reasonably estimated at this time but may materially affect our ability to operate our business and result in additional costs. It is not possible to reliably measure or quantify the impact COVID-19 has had on the financial results of the Company. If the COVID-19 pandemic continues for an extended period, it may materially adversely impact business operations and, consequently, future financial results.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	10. Income Taxes The Company is subject to income taxes on an entity basis on income arising in or derived from the tax jurisdiction in which each entity is domiciled. The Company is subject to taxation in the US and Canada. The following table provides a breakdown of net loss between domestic and foreign jurisdictions for the years ended December 31, 2021 and 2020: Schedule of Net Loss Domestic and Foreign Jurisdictions December 31, 2021 December 31, 2020 Net loss - domestic $ (10,997,929 ) $ (5,845,053 ) Net loss foreign - - Total $ (10,997,929 ) $ (5,845,053 ) The 2017 Tax Act created a new requirement that, for the periods beginning after January 1, 2018, certain income (referred to as global intangible low taxed income or “GILTI”) earned by foreign subsidiaries in excess of a deemed return on tangible assets of foreign corporations must be included in U.S. taxable income. The GILTI income is eligible for a deduction, which lowers the effective tax rate to 10.5% 13.125% As of December 31, 2021, and 2020, the Company has net operating loss carry forwards of $ 41,706,000 30,971,000 expected to expire at various times through 2041 The Company’s tax expense differs from the “expected” tax expense for Federal income tax purposes (computed by applying the United States Federal tax rate of 21% Schedule of Income Tax Expense December 31, 2021 December 31, 2020 Tax expense (benefit) at the statutory rate $ (2,309,565 ) $ (1,227,461 ) Non-deductible items 620,855 384,991 Deferred true-ups (119,782 ) 124,206 Change in valuation allowance (2,309,565 ) 718,264 Total $ - $ - The tax effects of the temporary differences between reportable financial statement income and taxable income are recognized as deferred tax assets and liabilities. The tax years 2021 and 2020 remain open to examination by federal agencies and other jurisdictions in which it operates. The tax effect of significant components of the Company’s deferred tax assets and liabilities at December 31, 2021 and 2020, are as follows: Schedule of Deferred Tax Assets and Liabilities December 31, 2021 December 31, 2020 Deferred tax assets: Net operating loss carryforward $ 8,758,337 $ 6,504,000 Lease liability 277,142 277,000 Deferred tax assets before valuation allowance 9,035,479 6,781,000 Less: deferred tax asset valuation allowance (5,093,324 ) (3,284,382 ) Total deferred tax asset after valuation allowance 3,942,155 3,496,618 Deferred tax liabilities: Intangible assets (3,665,013 ) (3,219,618 ) Fixed assets (277,142 ) (277,000 ) Total deferred tax liabilities 3,942,155 3,496,618 Total net deferred tax asset (liability) $ - $ - In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Because of the historical earnings history of the Company, the net deferred tax assets for 2021 and 2020 were fully offset by a 100% valuation allowance. The valuation allowance for the remaining net deferred tax assets was $ 5,093,000 3,284,000 On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows NOLs incurred in 2018, 2019, and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	11. Subsequent Events We evaluated subsequent events through the date on which the consolidated financial statements were issued and except as noted below, no events require recognition or disclosure. Subsequent to the year ended December 31, 2021, we conducted the following additional closings of our unit private placement in which we accepted the indicated non-cash forms of consideration in exchange for units in the private placement: ● On January 13, 2022, we issued to a consultant 22,857 1.75 40,000 45,714 ● On January 24, 2022, we issued to two unrelated investors a total of 159,245 1.75 278,678 218,490 ● On January 24, 2022, we issued to the representative and its designee, Bradley Richmond, our licensing and market advisor and former Acting Vice President of Finance, a total of 171,429 1.75 300,000 342,000 ● On January 26 and February 14, 2022, in exchange for services of Mr. Richmond, we granted to him 300,000 warrants to purchase an aggregate 300,000 shares of our common stock at an exercise price of $ 0.01 per share. On March 15, 2022, Mr. Richmond exercised 300,000 of warrants issued to him subsequently to the year end, upon which Marizyme issued to Mr. Richmond 300,000 shares of common stock.

Organization, Basis of Presen_2

Organization, Basis of Presentation and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Organization	Organization Maryzime, Inc. (the “Company” or “Marizyme”) is a Nevada corporation originally incorporated on March 20, 2007, under the name SWAV Enterprises, Ltd. On September 6, 2010, the Company name was changed to GBS Enterprises Inc. and from 2010 to September 2018 the Company was in the software products and advisory services business for email and instant messaging applications. The Company divested that business between December 2016 and September 2018 and focused on the acquisition of life science technologies. On March 21, 2018, the Company’s name was changed to Marizyme, Inc., to reflect the new life sciences focus. Marizyme’s common stock is currently quoted on the OTC Markets’ QB tier under the symbol “MRZM”.
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The Company’s consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The accompanying consolidated financial statements include the consolidated accounts of the Company and its wholly owned subsidiaries, Somahlution, Inc. (“Somahlution”), Somaceutica, Inc. (“Somaceutica”), Marizyme Sciences, Inc. (“Marizyme Sciences”), and My Health Logic, Inc. (“My Health Logic”). All intercompany transactions have been eliminated on consolidation.
Going Concern	Going Concern The Company’s consolidated financial statements are prepared using principals generally accepted in the United States of America applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, the Company does not have an established source of revenues sufficient to cover its operating costs and to allow it to continue as a going concern. The Company, since its inception, has incurred recurring operating losses and negative cash flows from operations and has an accumulated deficit of $ 47,823,563 at December 31, 2021. Additionally, the Company has working capital of $ 1,268,097 and $ 4,072,339 of cash on hand, which may not be sufficient to fund operations for the next twelve months. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Under the going concern assumption, an entity is ordinarily viewed as continuing its business for the foreseeable future with neither the intention or necessity of liquidation, ceasing trading, or seeking protection from creditors pursuant to the laws and regulations. Accordingly, assets and liabilities are recorded on the basis that the entity will be able to realize its assets and discharge its liabilities in the normal course of business. The ability of the Company to continue as a going concern is dependent upon its ability to continue to successfully develop its intangible assets, receive an approval from the U.S. Federal and Drug Administration to extend the selling of the products into the U.S. market which will allow the Company to attain profitable operations. During the next twelve months from the date the consolidated financial statements were issued, the Company’s foreseeable cash requirements will relate to continuous operations of its business, maintaining its good standing and making the required filing with the SEC, and the payment of expenses associated with its product development. The Company may experience a cash shortfall and be required to raise additional capital. Management intends to raise additional funds by way of a private or public offering. Subsequent to the year ended December 31, 2021, on February 14, 2021, Marizyme completed a preliminary prospectus with intention to raise up to $ 17,250,000 The consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make use of certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reported periods. The Company bases its estimates on historical experience and on various other assumptions that management believes are reasonable under the circumstances, the results of which form the basis for making judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. Significant estimates are related to the allocation of the purchase price in a business combination to the underlying assets and liabilities, recoverability of long-term assets including intangible assets and goodwill, amortization expense, valuation of warrants, stock-based compensation, derivative liabilities, contingent liabilities, and deferred tax valuations.
Fair Value Measurements	Fair Value Measurements The Company uses the fair value hierarchy to measure the value of its financial instruments. The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair value that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources, while unobservable inputs reflect a reporting entity’s pricing based upon its own market assumptions. The basis for fair value measurements for each level within the hierarchy is described below: ● Level 1 – Quoted prices for identical assets or liabilities in active markets. ● Level 2 – Quoted prices for identical or similar assets and liabilities in markets that are not active; or other model-derived valuations whose inputs are directly or indirectly observable or whose significant value drivers are observable. ● Level 3 – Valuations derived from valuation techniques in which one or more significant inputs to the valuation model are unobservable and for which assumptions are used based on management estimates. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value. The fair value of lease obligations is determined using discounted cash flows based on the expected amounts and timing of the cash flows discounted using a market rate of interest adjusted for appropriate credit risk. The contingent liabilities assumed on the acquisition of Somah (Note 2) consist of present values of royalty payments, performance warrants and pediatric voucher warrants, future rare pediatric voucher sales, and liquidation preference. Management measured these contingencies in accordance with Level 3 of the fair value hierarchy. i. The performance warrants and pediatric vouchers warrants liabilities were valued using a Monte Carlo simulation model utilizing the following weighted average assumptions: risk free rate of 1.19 69.62 0 6.21 417,000 4,352,000 ii. The present value of royalty payments was measured using the scenario-based methodology. In assessing the value attributed to the royalty payments, the estimated future cash flows were discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the revenue from net sales of the product. The cash flows derived from the Company’s fifteen-year strategic plan are based on managements’ expectations of market growth, industry reports and trends, and past performances. These projections are inherently uncertain due to the evolving impact of the COVID-19 pandemic. The discounted cash flow model included projections surrounding revenue, discount rates, and growth rates. The discount rates used to calculate the present value of royalty payments reflect specific risks of the Company and market conditions and the mid-range was estimated at 20.6 1,802,000 3,988,000 iii. Rare pediatric voucher sales liability was valued based on the scenario-based methodology where the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset – 20.6 2,000 1,150,000 iv. The present value of liquidation preference liability, included in the contingent consideration, was determined using the Black-Scholes option pricing method and represents the fair value of the maximum payment amount according to the Agreement. The following assumptions were used in the Black-Scholes option pricing model: risk free rate of 0.21 78.93 0 5 years No 1,823,000 The derivative liabilities consisted of optional and automatic conversion features and the share redemption feature attached to the convertible notes, issued pursuant to the Unit Purchase Agreement (Note 6). The Company has no financial assets measured at fair value on a recurring basis. None of the Company’s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented. Marizyme measures the following financial instruments at fair value on a recurring basis. At December 31, 2021 and 2020, the fair values of these financial instruments were as follows: Schedule Of Fair Values of Financial Instruments December 31, 2021 Level 1 Level 2 Level 3 December 31, 2020 Fair Value Hierarchy December 31, 2021 Level 1 Level 2 Level 3 December 31, 2020 Liabilities Derivative liabilities $ - $ - $ 2,485,346 $ - Contingent liabilities - - 11,313,000 - Total $ - $ - $ 13,798,346 $ - The following table provides a roll forward of all liabilities measured at fair value using Level 3 significant unobservable inputs: Schedule of Liabilities Fair Value Measured Derivative and Contingent Liabilities Balance at December 31, 2020 - Derivative liabilities $ 391,648 Extinguishment of debt obligations (391,648 ) Derivative liabilities - amended Unit Purchase Agreement (Note 6) 2,485,346 Initial valuation of contingent liabilities assumed on Somah acquisition 1 9,926,000 Change in fair value 1,387,000 Balance at December 31, 2021 $ 13,798,346 1 Measured as at Somah acquisition date of July 31, 2020, see Note 2.
Cash	Cash Cash include cash in readily available checking accounts.
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.
Inventory	Inventory Inventory consisted of primarily finished goods and is valued at the lower of cost and net realizable value. Cost is determined using the FIFO method. The Company decreases the value of inventory for estimated obsolescence equal to the difference between the cost of inventory and the estimated market value, based upon an aging analysis of the inventory on hand, specifically known inventory-related risks, and assumptions about future demand and market conditions. The Company has determined that no inventory reserve was necessary as of December 31, 2021 and 2020.
Accounts Receivable	Accounts Receivable Trade receivables are amounts due from customers for goods sold in the ordinary course of business. Accounts receivable are non-interest bearing and are due for settlement in full within 30 days. Trade receivables are shown net of allowance for bad or doubtful debts.
Allowance for Doubtful Accounts	Allowance for Doubtful Accounts The Company establishes an allowance for doubtful accounts to ensure trade and other receivables are not overstated due to non-collectability. The Company’s allowance is based on a variety of factors, including age of the receivable, significant one-time events, historical experience, and other risk considerations. The Company did not have an allowance at December 31, 2021 or 2020. The Company did not record any bad debt expense in each of the years ended December 31, 2021 and 2020.
Property, Plant, and Equipment, Net	Property, Plant, and Equipment, Net Property, plant and equipment are recorded at cost, less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the useful life of the asset. Machinery, computer equipment and related software are depreciated over five to seven years. Furniture and fixtures are depreciated over four seven years
Intangible Assets and Goodwill	Intangible Assets and Goodwill Intangible assets are recorded at cost less accumulated amortization and accumulated impairment losses. Intangible assets acquired as a result of an acquisition or in a business combination are measured at fair value at the acquisition date. The useful lives of intangible assets are assessed as either finite or indefinite. Intangible assets with finite lives are amortized over the estimated useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The estimated useful life and amortization method are reviewed at the end of each reporting period, with the effect of any changes in estimates being accounted for on a prospective basis. Goodwill represents the excess of the purchase price paid for the acquisition of subsidiaries over the fair value of the net assets acquired. Following the initial recognition, goodwill is measured at cost less any accumulated impairment losses.
In-Process Research and Development	In-Process Research and Development The Company evaluates whether acquired intangible assets are a business under applicable accounting standards. Additionally, the Company evaluates whether the acquired assets have a future alternative use. Intangible assets that do not have future alternative use are considered acquired in-process research and development (“IPR&D”). When the acquired in-process research and development assets are not part of a business combination, the value of the consideration paid is expensed on the acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred. These IPR&D assets are reviewed for impairment annually, or sooner if events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable, and upon establishment of technological feasibility or regulatory approval. An impairment loss, if any, is calculated by comparing the fair value of the asset to its carrying value. If the asset’s carrying value exceeds its fair value, an impairment loss is recorded for the difference and its carrying value is reduced accordingly. Similar to the impairment test for goodwill, the Company may perform a qualitative approach for testing indefinite-lived intangible assets for impairment. The Company used the qualitative approach and concluded that it was more-likely-than-not that its indefinite-lived assets were not impaired during the years ended December 31, 2021 and 2020.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company reviews long-lived assets, including property, plant and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount. The impairment loss, if recognized, would be based on the excess of the carrying value of the impaired asset over its respective fair value. No impairment losses have been recorded through December 31, 2021 and 2020.
Leases	Leases At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company records the associated lease liability and corresponding right-of-use asset upon commencement of the lease using the implicit rate or a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. The Company additionally evaluates leases at their inception to determine if they are to be accounted for as an operating lease or a finance lease. A lease is accounted for as a finance lease if it meets one of the following five criteria: the lease has a purchase option that is reasonably certain of being exercised, the present value of the future cash flows is substantially all of the fair market value of the underlying asset, the lease term is for a significant portion of the remaining economic life of the underlying asset, the title to the underlying asset transfers at the end of the lease term, or if the underlying asset is of such a specialized nature that it is expected to have no alternative uses to the lessor at the end of the term. Leases that do not meet the finance lease criteria are accounted for as an operating lease. Operating lease assets represent a right to use an underlying asset for the lease term and operating lease liabilities represent an obligation to make lease payments arising from the lease. Operating lease liabilities with a term greater than one year and their corresponding right-of-use assets are recognized on the balance sheet at the commencement date of the lease based on the present value of lease payments over the expected lease term. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. As the Company’s leases do not typically provide an implicit rate, the Company utilizes the appropriate incremental borrowing rate, determined as the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and in a similar economic environment. Lease cost is recognized on a straight-line basis over the lease term and variable lease payments are recognized as operating expenses in the period in which the obligation for those payments is incurred. Variable lease payments primarily include common area maintenance, utilities, real estate taxes, insurance, and other operating costs that are passed on from the lessor in proportion to the space leased by the Company. The Company has elected the practical expedient to not separate between lease and non-lease components.
Revenue Recognition	Revenue Recognition Pursuant to Topic 606, the Company recognizes revenue to depict the transfer of promised goods or services to a customer in an amount that reflects the consideration to which the entity expects to be intitled in exchange for those goods or services. To achieve this core principle, Topic 606 outlines a five-step process for recognizing revenue from customer contracts that includes i) identification of the contract with a customer, ii) identification of the performance obligations in the contract, iii) determining the transaction price, iv) allocating the transaction price to the separate performance obligations in the contract, and v) recognizing revenue associated with performance obligations as they are satisfied. At contract inception, the Company assesses the goods or services promised within each contract and assess whether each promised good or service is distinct and determine those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied. We have identified one performance obligation which is related to our DuraGraft product sales. For our Distribution Partner channel, we recognize revenue for product sales at the time of delivery of the product to our Distribution Partner (customer). As our products have an expiration date, if a product expires, we will replace the product at no charge. There were no significant judgements made in applying this topic.
Direct Cost of Revenue	Direct Cost of Revenue Cost of sales includes the actual cost of merchandise sold, and the cost of transportation of merchandise from our third-party vendor to our distributer.
Research and Development Expenses and Accruals	Research and Development Expenses and Accruals All research and development costs are expensed in the period incurred and consist primarily of salaries, payroll taxes, and employee benefits, those individuals involved in research and development efforts, external research and development costs incurred under agreements with contract research organizations and consultants to conduct and support the Company’s ongoing clinical trials of Duragraft, and costs related to manufacturing Duragraft for clinical trials. The Company has entered into various research and development contracts with various organizations and other companies. Payments of these activities are based on the terms of the individual agreements which matches to the pattern of costs incurred. Payments made in advances are reflected in the accompanying balance sheets as prepaid expenses. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates.
Stock-Based Compensation	Stock-Based Compensation Share-based compensation expense for employees and directors is recognized in the Consolidated Statement of Operations based on estimated amounts, including the grant date fair value and the expected service period. For stock options, we estimate the grant date fair value using a Black-Scholes valuation model, which requires the use of multiple subjective inputs including estimated future volatility, expected forfeitures and the expected term of the awards. We estimate the expected future volatility based on the stock’s historical price volatility. The stock’s future volatility may differ from the estimated volatility at the grant date. For restricted stock unit (“RSU”) equity awards, we estimate the grant date fair value using our closing stock price on the date of grant. We recognize the effect of forfeitures in compensation expense when the forfeitures occur. The estimated forfeiture rates may differ from actual forfeiture rates which would affect the amount of expense recognized during the period. We recognize the value of the awards over the awards’ requisite service or performance periods. The requisite service period is generally the time over which our share-based awards vest.
Income Taxes	Income Taxes The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the statement of operations in the period that includes the enactment date. The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. The Company records uncertain tax positions on the basis of a two-step process whereby (i) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability. There were no interest and penalties as of December 31, 2021 and 2020.
Segment Reporting	Segment Reporting Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as one
Net Loss Per Share	Net Loss Per Share Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Dilutive common stock equivalents are comprised of unvested common stock, options and warrants. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities (warrants, stock options, and common shares subject to repurchase) would be antidilutive.
Comparative Information	Comparative Information To conform with the current year’s financial statement presentation, the Company reclassified certain professional fees, salaries, and rent expenses related to research and development activities for the year ended December 31, 2020 into research and development expenses line item on the Consolidated Statements of Operations. Such reclassifications were not considered material and did not have any effect on the Company’s net loss for the year ended December 31, 2020.
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards In December 2019, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board or other standard setting bodies on the Company’s consolidated financial statements as well as material updates to previous assessments. There were no new material accounting standards issued or adopted in year of 2021 that impacted the Company.

Organization, Basis of Presen_3

Organization, Basis of Presentation and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Schedule Of Fair Values of Financial Instruments	Marizyme measures the following financial instruments at fair value on a recurring basis. At December 31, 2021 and 2020, the fair values of these financial instruments were as follows: Schedule Of Fair Values of Financial Instruments December 31, 2021 Level 1 Level 2 Level 3 December 31, 2020 Fair Value Hierarchy December 31, 2021 Level 1 Level 2 Level 3 December 31, 2020 Liabilities Derivative liabilities $ - $ - $ 2,485,346 $ - Contingent liabilities - - 11,313,000 - Total $ - $ - $ 13,798,346 $ -
Schedule of Liabilities Fair Value Measured	The following table provides a roll forward of all liabilities measured at fair value using Level 3 significant unobservable inputs: Schedule of Liabilities Fair Value Measured Derivative and Contingent Liabilities Balance at December 31, 2020 - Derivative liabilities $ 391,648 Extinguishment of debt obligations (391,648 ) Derivative liabilities - amended Unit Purchase Agreement (Note 6) 2,485,346 Initial valuation of contingent liabilities assumed on Somah acquisition 1 9,926,000 Change in fair value 1,387,000 Balance at December 31, 2021 $ 13,798,346

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2021
Business Combination and Asset Acquisition [Abstract]
Schedule of Preliminary Allocation of Consideration	Details of the carrying amount and the fair value of identifiable assets and liabilities acquired and purchase consideration paid are as follows: Schedule of Preliminary Allocation of Consideration Consideration Common shares $ 12,500,000 Warrants 1,200,000 Contingent consideration 1 9,926,000 Total consideration $ 23,626,000 Fair value of identifiable assets acquired, and liabilities assumed Net working capital $ 30,908 Property, plant, and equipment 9,092 Intangible assets 18,170,000 Goodwill 5,416,000 Total identifiable assets $ 23,626,000
Schedule of Assets and Liabilities Acquired and Purchase Consideration	Details of the carrying amount and the fair value of identifiable assets and liabilities acquired and purchase consideration paid are as follows: Schedule of Assets and Liabilities Acquired and Purchase Consideration Consideration given up Common shares $ 7,774,000 Total consideration given up $ 7,774,000 Fair value of identifiable assets acquired, and liabilities assumed Net working deficit $ (613,156 ) Property, plant, and equipment 12,500 Intangible assets 6,600,000 Goodwill 1,774,656 Total identifiable assets $ 7,774,000

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2021
Leases
Schedule of Right-of-Use Asset and Related Lease Liabilities	The following table summarizes supplemental balance sheet information related to the operating lease as of December 31, 2021: Schedule of Right-of-Use Asset and Related Lease Liabilities December 31, December 31, Right-of-use asset $ 1,158,776 $ 1,317,830 Operating lease liabilities, current $ 277,142 $ 243,292 Operating lease liabilities, non-current 881,634 1,074,538 Total operating lease liabilities $ 1,158,776 $ 1,317,830
Schedule of Maturities of the Lease Liabilities	As at December 31, 2021, the maturities of the lease liabilities for the periods ended December 31 were as follows: Schedule of Maturities of the Lease Liabilities 2022 $ 277,142 2023 277,142 2024 277,142 2025 277,142 Thereafter 130,950 Total lease payments 1,239,518 Less: Present value discount (80,742 ) Total $ 1,158,776

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets Amortization Expense	As part of My Health Logic acquisition (Note 2), Marizyme purchased MHL’s lab-on-chip technology platform and its patient-centric, digital point-of-care diagnostic device, MATLOC, fair valued at an aggregate amount of $ 6,600,000 Schedule of Intangible Assets Amortization Expense Intangible Assets December 31, 2021 December 31, 2020 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Krillase intangible assets $ 28,600,000 $ - $ 28,600,000 $ 28,600,000 $ - $ 28,600,000 Patents in process 122,745 - 122,745 119,971 - 119,971 DuraGraft patent 5,256,000 (572,768 ) 4,683,232 14,147,729 (589,489 ) 13,558,240 Duragraft - Distributor relationship 308,000 (43,633 ) 264,367 - - - Duragraft IPR&D - Cyto Protectant Life Sciences 12,606,000 - 12,606,000 - - - My Health Logic - Trade name 450,000 (804 ) 449,196 - - - My Health Logic - Biotechnology 4,600,000 (6,765 ) 4,593,235 - - - My Health Logic - Software 1,550,000 (2,583 ) 1,547,417 - - - Total intangible assets $ 53,492,745 $ (626,553 ) $ 52,866,192 $ 42,867,700 $ (589,489 ) $ 42,278,211
Schedule of Goodwill	Schedule of Goodwill Goodwill DuraGraft My Health Logic Total Balance, December 31, 2020 $ - $ - $ - Additions on acquisitions 5,416,000 1,774,656 7,190,656 Impairment - - - Balance, December 31, 2021 $ 5,416,000 $ 1,774,656 $ 7,190,656
Schedule of Intangible Assets	The following changes to the Company’s intangible assets had taken place in the periods indicated: Schedule of Intangible Assets Balance, December 31, 2019 $ 28,613,000 Acquired in asset purchase agreement 14,147,729 Additions 106,971 Amortization expense (589,489 ) Balance, December 31, 2020 $ 42,278,211 Acquired in Somah Transaction 1 4,022,271 Acquired in MHL Transaction 6,600,000 Additions 2,775 Amortization expense 1 (37,065 ) Balance, December 31, 2021 $ 52,866,192 1 To account for Somah Transaction measurement period adjustments, the Company restated the Quarterly Report on Form 10-Q for the three and six month ended June 30, 2021, originally filed on August 23, 2021. As a result of the restatement, the value of DuraGraft intangibles purchased with the Somah Transaction increased by $ 4,022,271 898,026

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2021
Payables and Accruals [Abstract]
Schedule of Accounts Payable And Accrued Liabilities	Accounts payable and accrued expenses, summarized by major category, as of December 31, 2021 and 2020 consists of the following: Schedule of Accounts Payable And Accrued Liabilities December 31, 2021 December 31, Trade accounts payable $ 1,465,860 $ 325,830 Accrued expenses 8,215 21,555 Accrued compensation expenses 122,072 130,718 Total accounts payable and accrued expenses $ 1,596,147 $ 478,103

Convertible Promissory Notes _2

Convertible Promissory Notes and Warrants (Tables)	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Schedule of Convertible Notes	During the year ended December 31, 2021, the Company recognized interest and accretion expense of $ 116,676 Nil Schedule of Convertible Notes December 31, 2021 December 31, 2020 Convertible notes issued - original securities $ 1,174,945 $ Issuance costs (105,745 ) - Debt discount (964,153 ) - Debt accretion 90,611 - Extinguishment of debt in connection with December 2021 Exchange Agreements (195,658 ) - Convertible notes issued - new securities, outstanding at December 31, 2021 7,456,039 - Issuance costs (671,044 ) Debt discount (6,784,995 ) - Debt accretion 26,065 - Convertible notes, net of debt discount $ 26,065 $ -

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Schedule of Share Based Stock Option Valuation Assumptions	Schedule of Share Based Stock Option Valuation Assumptions 2021 2020 Risk-free interest rate 1.09 % 0.93 % Volatility 252.08 % 241.88 % Exercise price $ 1.51 $ 1.37 Dividend yield 0 % 0 % Forfeiture rate 0 % 0 % Expected life (years) 6.38 10.00
Schedule of Stock Option Activities	The summary of option activity for the years ended December 31, 2021 and 2020 was as follows: Schedule of Stock Option Activities Number of Options Weighted Average Exercise Price Weighted Average Contractual Life Total Intrinsic Value Outstanding at December 31, 2019 2,715,000 $ 1.50 9.48 Granted 1,340,000 1.25 Exercised (254,057 ) 1.02 Outstanding at December 31, 2020 3,800,943 $ 1.36 8.82 Granted 1,532,500 1.51 Forfeited (1,682,500 ) 1.36 Outstanding at December 31, 2021 3,650,943 $ 1.24 8.34 $ 1,951,117 Exercisable at December 31, 2021 2,399,371 $ 1.07 7.70 $ 1,685,099
Schedule of Options Outstanding and Exercisable	As of December 31, 2021, the Company had the following options issued and outstanding: Schedule of Options Outstanding and Exercisable Exercise Price Number of Options Outstanding Number of Options Exercisable Weighted Average Remaining Contractual Years Intrinsic Value $ 1.01 1,985,943 1,985,943 7.43 $ 1,509,317 1.25 665,000 213,428 9.09 110,983 1.37 200,000 160,000 8.63 64,000 1.75 800,000 40,000 9.84 800 $ 1.24 3,650,943 2,399,371 8.34 $ 1,951,117
Schedule of Warrants Outstanding	Schedule of Warrants Outstanding Number Weighted Average Price December 30, 2019 113,637 $ 3.00 Issued on Somah acquisition 3,000,000 5.00 Issued 280,014 1.38 December 30, 2020 3,393,651 $ 2.13 Issued pursuant to Unit Purchase Agreement 8,521,187 2.25 Issued 230,000 1.39 December 31, 2021 12,144,838 $ 2.20

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of Net Loss Domestic and Foreign Jurisdictions	Schedule of Net Loss Domestic and Foreign Jurisdictions December 31, 2021 December 31, 2020 Net loss - domestic $ (10,997,929 ) $ (5,845,053 ) Net loss foreign - - Total $ (10,997,929 ) $ (5,845,053 )
Schedule of Income Tax Expense	Schedule of Income Tax Expense December 31, 2021 December 31, 2020 Tax expense (benefit) at the statutory rate $ (2,309,565 ) $ (1,227,461 ) Non-deductible items 620,855 384,991 Deferred true-ups (119,782 ) 124,206 Change in valuation allowance (2,309,565 ) 718,264 Total $ - $ -
Schedule of Deferred Tax Assets and Liabilities	The tax effect of significant components of the Company’s deferred tax assets and liabilities at December 31, 2021 and 2020, are as follows: Schedule of Deferred Tax Assets and Liabilities December 31, 2021 December 31, 2020 Deferred tax assets: Net operating loss carryforward $ 8,758,337 $ 6,504,000 Lease liability 277,142 277,000 Deferred tax assets before valuation allowance 9,035,479 6,781,000 Less: deferred tax asset valuation allowance (5,093,324 ) (3,284,382 ) Total deferred tax asset after valuation allowance 3,942,155 3,496,618 Deferred tax liabilities: Intangible assets (3,665,013 ) (3,219,618 ) Fixed assets (277,142 ) (277,000 ) Total deferred tax liabilities 3,942,155 3,496,618 Total net deferred tax asset (liability) $ - $ -

Schedule Of Fair Values of Fina

Schedule Of Fair Values of Financial Instruments (Details) - USD ($)	Dec. 31, 2021	Dec. 21, 2021	Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Derivative liabilities		$ 2,485,346
Contingent liabilities	$ 11,313,000
Total
Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Derivative liabilities
Contingent liabilities
Total
Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Derivative liabilities
Contingent liabilities
Total
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Derivative liabilities	2,485,346
Contingent liabilities	11,313,000
Total	$ 13,798,346

Schedule of Liabilities Fair Va

Schedule of Liabilities Fair Value Measured (Details)	12 Months Ended
	Dec. 31, 2021USD ($)
Accounting Policies [Abstract]
Beginning Balance
Derivative liabilities	391,648
Extinguishment of debt obligations	(391,648)
Derivative liabilities - amended Unit Purchase Agreement (Note 6)	2,485,346
Initial valuation of contingent liabilities assumed on Somah acquisition1	9,926,000	[1]
Change in fair value	1,387,000
Ending Balance	$ 13,798,346
[1]	Measured as at Somah acquisition date of July 31, 2020, see Note 2.

Organization, Basis of Presen_4

Organization, Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)	3 Months Ended	12 Months Ended
	Mar. 29, 2022USD ($)	Dec. 31, 2021USD ($)Number	Dec. 31, 2020USD ($)
Property, Plant and Equipment [Line Items]
Retained Earnings (Accumulated Deficit)		$ 47,823,563	$ 36,825,634
Working Capital		1,268,097
Cash		$ 4,072,339
Risk free rate		1.09%	0.93%
Expected life		6 years 4 months 17 days	10 years
Midrange average estimated interest rate		20.60%
Liabilities fair value adjustment		$ 1,802,000
Royalties payable		3,988,000
Impairment of Long-Lived Assets		$ 0	$ 0
Number of operating segment | Number		1
[custom:NewAccountingPronouncements]		$ 0
Minimum [Member]
Property, Plant and Equipment [Line Items]
Furniture and fixtures depreciated		4 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Furniture and fixtures depreciated		7 years
Scenario, Adjustment [Member]
Property, Plant and Equipment [Line Items]
Liabilities fair value adjustment		$ 2,000
Pre tax discount rate percentage		20.60%
Market value		$ 1,150,000
Warrants Liabilities [Member]
Property, Plant and Equipment [Line Items]
Risk free rate		1.19%
Expected volatility		69.62%
Expected dividend		$ 0
Expected life		6 years 2 months 15 days
Increase (Decrease) in Operating Liabilities		$ 417,000
Warrants liabilities		$ 4,352,000
Liquidation Preference [Member]
Property, Plant and Equipment [Line Items]
Risk free rate		0.21%
Expected volatility		78.93%
Expected dividend		$ 0
Expected life		5 years
Liquidation preference value		$ 0
Liquidation preference fair market value		$ 1,823,000
Subsequent Event [Member]
Property, Plant and Equipment [Line Items]
Proceeds from offering	$ 17,250,000

Schedule of Preliminary Allocat

Schedule of Preliminary Allocation of Consideration (Details) - Duragraft [Member]	12 Months Ended
	Dec. 31, 2021USD ($)
Business Acquisition [Line Items]
Common shares	$ 12,500,000
Warrants	1,200,000
Contingent consideration	9,926,000	[1]
Total consideration	23,626,000
Net working capital	30,908
Property, plant, and equipment	9,092
Intangible assets	18,170,000
Goodwill	5,416,000
Total identifiable assets	$ 23,626,000
[1]	During the year ended December 31, 2021,

Schedule of Preliminary Alloc_2

Schedule of Preliminary Allocation of Consideration (Details) (Parenthetical) - USD ($)	Dec. 31, 2021	Jul. 31, 2020
Somah Acquisition [Member]
Business Acquisition [Line Items]
Business Combination, Contingent Consideration, Liability	$ 11,313,000	$ 1,387,000

Schedule of Assets and Liabilit

Schedule of Assets and Liabilities Acquired and Purchase Consideration (Details) - My HealthLogic [Member]	12 Months Ended
	Dec. 31, 2021USD ($)
Business Acquisition [Line Items]
Common shares	$ 7,774,000
Total consideration	7,774,000
Net working deficit	(613,156)
Property, plant, and equipment	12,500
Intangible assets	6,600,000
Goodwill	1,774,656
Total identifiable assets	$ 7,774,000

Acquisitions (Details Narrative

Acquisitions (Details Narrative) - USD ($)	Dec. 22, 2021	Jul. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Aug. 03, 2020
Business Acquisition [Line Items]
Prepaid royalties non current			$ 339,091	$ 344,321
Warrants to purschase common stock			250,000		229,499
Stike price per share					$ 1.375
Warrants term					5 years
Revenue, remaining performance obligation, percentage			6.00%
Additional revenues			$ 50,000,000
Deferred revenue, period increase (decrease)			$ 200,000,000
Economic life			10 years
Percentage of Weighted Average Cost Inventory			33.80%
Common stock, shares, issued			40,528,188	35,928,188
Common stock, shares, outstanding			40,528,188	35,928,188
Trade Names [Member]
Business Acquisition [Line Items]
Economic life			14 years
Marizyme [Member]
Business Acquisition [Line Items]
Common stock, shares, issued	40,528,188
Duragraft [Member]
Business Acquisition [Line Items]
Economic life			13 years
HL two holdings [Member]
Business Acquisition [Line Items]
Stock exchange acquisition common stock	$ 4,600,000
Common stock issued	230,000
Acquisition	11.35%
Common stock, shares, outstanding	40,528,188
Somah Acquisition [Member]
Business Acquisition [Line Items]
Purchase price consideration		$ 9,926,000
Business Combination, Contingent Consideration, Liability		$ 1,387,000	$ 11,313,000
My HealthLogic [Member]
Business Acquisition [Line Items]
Purchase price consideration			$ 7,774,000
Percentage of Weighted Average Cost Inventory			37.50%
Notes payable			$ 468,137
Notes payable interest rate			9.00%
Debt maturity date			Aug. 12, 2022
Interest expense on notes payable			$ 1,115
My HealthLogic [Member] | Software [Member]
Business Acquisition [Line Items]
Economic life			15 years
My HealthLogic [Member] | Lab on Chip Technology [Member]
Business Acquisition [Line Items]
Remaining Useful Life			17 years
Royalty [Member]
Business Acquisition [Line Items]
Revenue, remaining performance obligation, percentage			5.00%
Additional revenues			$ 50,000,000
Subsequent sale percentage			10.00%
Royalty [Member] | Minimum [Member]
Business Acquisition [Line Items]
Revenue, remaining performance obligation, percentage			4.00%
Sale proceeds liquidation preference			15.00%
Royalty [Member] | Maximum [Member]
Business Acquisition [Line Items]
Revenue, remaining performance obligation, percentage			2.00%
Deferred revenue, period increase (decrease)			$ 50,000,000
Deferred revenue, revenue recognized			200,000,000
Liquidation preference			$ 20,000,000
Restricted Stock [Member]
Business Acquisition [Line Items]
Stock issued during period, shares, issued for services			10,000,000
Warrants to purschase common stock			3,000,000
Stike price per share			$ 5
Warrants term			5 years
Restricted Stock [Member] | Performance Warrants [Member]
Business Acquisition [Line Items]
Warrants to purschase common stock			4,000,000

Schedule of Right-of-Use Asset

Schedule of Right-of-Use Asset and Related Lease Liabilities (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Leases
Right-of-use asset	$ 1,158,776	$ 1,317,830
Operating lease liabilities, current	277,142	243,292
Operating lease liabilities, non-current	881,634	1,074,538
Total operating lease liabilities	$ 1,158,776	$ 1,317,830

Schedule of Maturities of the L

Schedule of Maturities of the Lease Liabilities (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Leases
2022	$ 277,142
2023	277,142
2024	277,142
2025	277,142
Thereafter	130,950
Total lease payments	1,239,518
Less: Present value discount	(80,742)
Total	$ 1,158,776	$ 1,317,830

Leases (Details Narrative)

Leases (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 11, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Lease term			5 years 6 months
Operating Expenses	$ 9,031,662	$ 5,996,739
Remaining Lease Term	4 years 5 months 1 day
Operating lease agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments for Rent		$ 10,817
Base Rent Percentage		2.50%
Operating Expenses		$ 12,000
Lessee, Operating Lease, Discount Rate	3.95%

Schedule of Intangible Assets A

Schedule of Intangible Assets Amortization Expense (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 53,492,745	$ 42,867,700
Accumulated amortization	(626,553)	(589,489)
Net carrying amount	52,866,192	42,278,211
Krillase Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	28,600,000	28,600,000
Accumulated amortization
Net carrying amount	28,600,000	28,600,000
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	122,745	119,971
Accumulated amortization
Net carrying amount	122,745	119,971
Dura Graft Patent [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	5,256,000	14,147,729
Accumulated amortization	(572,768)	(589,489)
Net carrying amount	4,683,232	13,558,240
Dura Graft Distributor Relationship[Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	308,000
Accumulated amortization	(43,633)
Net carrying amount	264,367
Duragraft Cyto Protectant [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	12,606,000
Accumulated amortization
Net carrying amount	12,606,000
My Health Logic Trade Name [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	450,000
Accumulated amortization	(804)
Net carrying amount	449,196
My Health Logic Biotechnology [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	4,600,000
Accumulated amortization	(6,765)
Net carrying amount	4,593,235
My Health Logic Software [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	1,550,000
Accumulated amortization	(2,583)
Net carrying amount	$ 1,547,417

Schedule of Goodwill (Details)

Schedule of Goodwill (Details)	12 Months Ended
	Dec. 31, 2021USD ($)
Impairment Effects on Earnings Per Share [Line Items]
Balance, December 31, 2020
Additions on acquisitions	7,190,656
Impairment
Balance, December 31, 2021	7,190,656
Duragraft [Member]
Impairment Effects on Earnings Per Share [Line Items]
Balance, December 31, 2020
Additions on acquisitions	5,416,000
Impairment
Balance, December 31, 2021	5,416,000
My HealthLogic [Member]
Impairment Effects on Earnings Per Share [Line Items]
Balance, December 31, 2020
Additions on acquisitions	1,774,656
Impairment
Balance, December 31, 2021	$ 1,774,656

Schedule of Intangible Assets (

Schedule of Intangible Assets (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021		Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Beginning Balance	$ 42,278,211		$ 28,613,000
Acquired in Somah Transaction	4,022,271	[1]	14,147,729
Additions	2,775		106,971
Amortization expense	(37,065)	[1]	(589,489)
Acquired in MHL Transaction	6,600,000
Ending Balance	$ 52,866,192		$ 42,278,211
[1]	To account for Somah Transaction measurement period adjustments, the Company restated the Quarterly Report on Form 10-Q for the three and six month ended June 30, 2021, originally filed on August 23, 2021. As a result of the restatement, the value of DuraGraft intangibles purchased with the Somah Transaction increased by $ 4,022,271 898,026

Schedule of Intangible Assets_2

Schedule of Intangible Assets (Details) (Parenthetical)	12 Months Ended
	Dec. 31, 2021USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of Intangible Assets	$ 4,022,271
Amortization of intangible assets	$ 898,026

Intangible Assets and Goodwil_2

Intangible Assets and Goodwill (Details Narrative) - USD ($)	Sep. 12, 2018	Dec. 31, 2021	Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Stock Issued During Period, Value, Acquisitions		$ 7,774,000	$ 12,500,000
Intangible Assets, Current		18,170,000
Impairment of intangible assets		0	0
Amortization expense		37,066	$ 589,489
Somah [Member]
Defined Benefit Plan Disclosure [Line Items]
Finite-lived intangible asset, expected amortization, year one		841,172
Finite-lived intangible asset, expected amortization, year two		$ 7,331,585
Krillase Technology [Member]
Defined Benefit Plan Disclosure [Line Items]
Stock Issued During Period, Value, Acquisitions	$ 28,600,000

Schedule of Accounts Payable An

Schedule of Accounts Payable And Accrued Liabilities (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Payables and Accruals [Abstract]
Trade accounts payable	$ 1,465,860	$ 325,830
Accrued expenses	8,215	21,555
Accrued compensation expenses	122,072	130,718
Total accounts payable and accrued expenses	$ 1,596,147	$ 478,103

Schedule of Convertible Notes (

Schedule of Convertible Notes (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Short-term Debt [Line Items]
Convertible notes, net of debt discount	$ 26,065
Original Securities [Member]
Short-term Debt [Line Items]
Convertible notes issued - new securities, outstanding at December 31, 2021	1,174,945
Issuance costs	(105,745)
Debt discount	(964,153)
Debt accretion	90,611
Extinguishment of debt in connection with December 2021 Exchange Agreements	(195,658)
New Securities [Member]
Short-term Debt [Line Items]
Convertible notes issued - new securities, outstanding at December 31, 2021	7,456,039
Issuance costs	(671,044)
Debt discount	(6,784,995)
Debt accretion	$ 26,065

Convertible Promissory Notes _3

Convertible Promissory Notes and Warrants (Details Narrative)	Dec. 21, 2021USD ($)$ / sharesshares	Dec. 21, 2021USD ($)$ / sharesshares	Sep. 29, 2021$ / shares	May 31, 2021USD ($)$ / sharesshares	May 27, 2021$ / sharesshares	Jul. 31, 2021USD ($)shares	May 31, 2021USD ($)$ / sharesshares	Dec. 31, 2021USD ($)$ / sharesshares	Dec. 31, 2020USD ($)	Aug. 03, 2020$ / sharesshares
Short-term Debt [Line Items]
Sale of stock, number of shares issued in transaction | shares							29,978
Sale of stock, price per share				$ 2.50			$ 2.50
Proceeds from notes Payable | $				$ 74,945				$ 263,907
Sale of stock amount | $						$ 1,100,000	$ 74,945
Warrants to purchase common shares | shares								250,000		229,499
Issuance costs | $				$ 6,745			6,745
Exercise price of warrants or rights										$ 1.375
Pro-rata Units | shares	621,087	621,087
Aggregate pro rata units | shares	832,022	832,022
Loss on debt extinguishment | $								$ 663,522
Fair value of warrant | $	$ 4,299,649							$ 4,447,982
Fair value of derivative liability | $	$ 2,485,346	$ 2,485,346
Debt instrument conversion price								$ 1.75
Convertible Notes Payable [Member]
Short-term Debt [Line Items]
Frequency of periodic payment								The Convertible Notes mature in 24 months from the initial closing date and accrue 10% of simple interest per annum on the outstanding principal amount
Debt instrument conversion description								The Convertible Notes principal and accrued interest can be converted at any time at the option of the holder at a conversion price of $1.75 per share (previously $2.25 per the September 2021 Amendment and originally $2.50 per the May Unit Purchase Agreement)
Percentage of debt instrument of conversion price								0.75
Maximum [Member]
Short-term Debt [Line Items]
Debt conversion price per share			$ 2.50
Minimum [Member]
Short-term Debt [Line Items]
Debt conversion price per share			2.25
Minimum [Member] | Convertible Notes Payable [Member]
Short-term Debt [Line Items]
Equity financing gross amount | $								$ 10,000,000
Class A Warrants [Member]
Short-term Debt [Line Items]
Sale of stock amount | $							$ 29,978
Warrants to purchase common shares | shares				29,978			29,978
New Class C Warrants [Member]
Short-term Debt [Line Items]
Percentage of debt instrument of conversion price								0.75
Debt instrument conversion price								$ 2.25
Warrants exercise price per share								$ 2.25
Warrants exercisable term								5 years
Percentage of warrant coverage								2
Unit Purchase Agreement [Member]
Short-term Debt [Line Items]
Sale of stock, number of shares issued in transaction | shares	3,438,572				4,000,000
Sale of stock, price per share	$ 1.75	$ 1.75			$ 2.50
Debt description	Each Unit is comprised of (i) a convertible promissory note convertible into common stock of the Company at an initial conversion price of $1.75 and, (ii) a warrant to purchase two shares of Common Stock at an initial purchase price of $2.25 per share (the new Class C Warrant)				Each Unit is comprised of (i) a convertible promissory note convertible into common stock of the Company, (ii) a warrant to purchase one share of common stock of the Company (the ‘Class A Warrant’); and (iii) a second warrant to purchase common stock of the Company (the “Class B Warrant”)
Sale of stock, consideration received on transaction | $	$ 6,000,000
Unit Purchase Agreement [Member] | Convertible Promissory Note [Member]
Short-term Debt [Line Items]
Sale of stock, number of shares issued in transaction | shares	9,714,286
Unit Purchase Agreement [Member] | Maximum [Member]
Short-term Debt [Line Items]
Sale of stock, price per share			2.50
Unit Purchase Agreement [Member] | Minimum [Member]
Short-term Debt [Line Items]
Sale of stock, price per share			$ 2.25
Unit Purchase Agreement [Member] | Class A Warrants [Member]
Short-term Debt [Line Items]
Warrants to purchase common shares | shares								469,978
Exercise price of warrants or rights								$ 3.13
Warrants exercisable term								5 years
Unit Purchase Agreement [Member] | Class B Warrants [Member]
Short-term Debt [Line Items]
Warrants to purchase common shares | shares								469,978
Exercise price of warrants or rights								$ 5
Warrants exercisable term								5 years
Unit Purchase Agreement [Member] | New Class C Warrants [Member]
Short-term Debt [Line Items]
Warrants to purchase common shares | shares	6,857,143	6,857,143
Exercise price of warrants or rights	$ 2.25	$ 2.25
Warrants exercisable term		5 years
Unit Purchase Program [Member]
Short-term Debt [Line Items]
Sale of stock, number of shares issued in transaction | shares						440,000
Proceeds from notes Payable | $						$ 1,100,000
Unit Purchase Program [Member] | Class A Warrants [Member]
Short-term Debt [Line Items]
Warrants to purchase common shares | shares						440,000
Unit Purchase Program [Member] | Class B Warrants [Member]
Short-term Debt [Line Items]
Warrants to purchase common shares | shares						440,000
December 2021 Exchange Agreement [Member]
Short-term Debt [Line Items]
Investments | $	$ 6,000,000	$ 6,000,000
Debt instrument, maturity date		Dec. 21, 2023
Exercise price of warrants or rights	$ 2.25	$ 2.25
Warrant coverage percentage	200.00%
December 2021 Exchange Agreement [Member] | Maximum [Member]
Short-term Debt [Line Items]
Sale of stock, price per share	$ 2.25	2.25
Debt conversion price per share	2.25
December 2021 Exchange Agreement [Member] | Minimum [Member]
Short-term Debt [Line Items]
Sale of stock, price per share	1.75	$ 1.75
Debt conversion price per share	$ 1.75

Schedule of Share Based Stock O

Schedule of Share Based Stock Option Valuation Assumptions (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Equity [Abstract]
Risk-free interest rate	1.09%	0.93%
Volatility	252.08%	241.88%
Exercise price	$ 1.51	$ 1.37
Dividend yield	0.00%	0.00%
Forfeiture rate	0.00%	0.00%
Expected life (years)	6 years 4 months 17 days	10 years

Schedule of Stock Option Activi

Schedule of Stock Option Activities (Details) - USD ($)	Apr. 06, 2020	Dec. 31, 2021	Dec. 31, 2020
Equity [Abstract]
Number of Options, Outstanding beginning Balance		3,800,943	2,715,000
Weighted Average Exercise Price, Outstanding beginning Balance		$ 1.36	$ 1.50
Weighted average contractual life term, outstanding			9 years 5 months 23 days
Number of Options, Granted		1,532,500	1,340,000
Weighted Average Exercise Price, Granted		$ 1.51	$ 1.25
Number of Options, Exercised	(5,000)		(254,057)
Weighted Average Exercise Price, Exercised			$ 1.02
Weighted average contractual life term, outstanding		8 years 4 months 2 days	8 years 9 months 25 days
Number of Options, Forfeited		(1,682,500)
Weighted Average Exercise Price, Forfeited		$ 1.36
Number of Options, Outstanding Ending Balance		3,650,943	3,800,943
Weighted Average Exercise Price, Outstanding Ending Balance		$ 1.24	$ 1.36
Total Intrinsic Value, Ending Balance		$ 1,951,117
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number		2,399,371
Weighted Average Exercise Price, Exercisable		$ 1.07
Weighted average contractual life term, exercisable		7 years 8 months 12 days
Total Intrinsic Value, exercisable		$ 1,685,099

Schedule of Options Outstanding

Schedule of Options Outstanding and Exercisable (Details)	12 Months Ended
	Dec. 31, 2021USD ($)$ / sharesshares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Intrinsic value | $	$ 1,951,117
Exercise Price Range 1.01 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price | $ / shares	$ 1.01
Share based compensation Number of option outstanding	1,985,943
Share based compensation number of options exercisable	1,985,943
Remaining Life in Years	7 years 5 months 4 days
Intrinsic value | $	$ 1,509,317
Exercise Price Range 1.25 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price | $ / shares	$ 1.25
Share based compensation Number of option outstanding	665,000
Share based compensation number of options exercisable	213,428
Remaining Life in Years	9 years 1 month 2 days
Intrinsic value | $	$ 110,983
Exercise Price Range 1.37 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price | $ / shares	$ 1.37
Share based compensation Number of option outstanding	200,000
Share based compensation number of options exercisable	160,000
Remaining Life in Years	8 years 7 months 17 days
Intrinsic value | $	$ 64,000
Exercise Price Range 1.75 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price | $ / shares	$ 1.75
Share based compensation Number of option outstanding	800,000
Share based compensation number of options exercisable	40,000
Remaining Life in Years	9 years 10 months 2 days
Intrinsic value | $	$ 800
Exercise Price Range 1.24 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price | $ / shares	$ 1.24
Share based compensation Number of option outstanding	3,650,943
Share based compensation number of options exercisable	2,399,371
Remaining Life in Years	8 years 4 months 2 days
Intrinsic value | $	$ 1,951,117

Schedule of Warrants Outstandin

Schedule of Warrants Outstanding (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted Average Exercise Price, Outstanding Ending Balance	$ 1.24	$ 1.36
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants outstanding, Begining balance	3,393,651	113,637
Weighted average exercise price, outstanding, beginning balance	$ 2.13	$ 3
Warrants outstanding, issued	230,000	280,014
Weighted average exercise price, issued	$ 1.39	$ 1.38
Warrants outstanding, Ending balance	12,144,838	3,393,651
Weighted Average Exercise Price, Outstanding Ending Balance	$ 2.20
Warrant [Member] | Unit Purchase Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted average exercise price, issued	$ 2.25
Issuance pursuant to unit purchase agreement	8,521,187
Warrant [Member] | Somah Acquisition [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants outstanding, issued		3,000,000
Weighted average exercise price, issued		$ 5

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)

Dec. 22, 2021

Dec. 21, 2021

Dec. 21, 2021

Sep. 29, 2021

Jan. 13, 2021

Oct. 01, 2020

Sep. 25, 2020

Sep. 02, 2020

Aug. 03, 2020

Jul. 31, 2020

Jul. 28, 2020

Jun. 08, 2020

Apr. 06, 2020

Jan. 09, 2020

Dec. 31, 2021

Dec. 31, 2020

Dec. 02, 2021

May 31, 2021

Class of Warrant or Right [Line Items]

Preferred stock, shares authorized

25,000,000

25,000,000

Preferred stock, par value per share

$ 0.001

$ 0.001

Preferred stock, shares issued

0

0

Preferred stock, shares outstanding

0

0

Common stock, shares authorized

75,000,000

75,000,000

Common Stock, Par or Stated Value Per Share

$ 0.001

$ 0.001

Common stock, shares issued

40,528,188

35,928,188

Common stock, shares issued

40,528,188

35,928,188

Stock issued during period, shares, new issues

4,600,000

20,000

160,000

125,000

Stock issued during period, value, new issues

$ 20,200

$ 161,600

$ 126,250

$ 6,275,164

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period

5,000

254,057

Stock issued during period services, value

$ 237,500

Stock issued during period acquisition, value

$ 7,774,000

12,500,000

Shares issued in aggregate

4,609,984

Shares issued, price per share

$ 1.25

Sale of stock, description of transaction

In consideration for services rendered as the placement agent in the private placement, the Company paid Univest Securities LLC cash commissions totaling $460,999, or 8% of the gross proceeds of the private placement closing, a 1% non-accountable expense allowance totaling $57,625, and the $31,250 balance (of a total of $37,500) due to the placement agent in advisory fees

Warrant term

5 years

Warrant to purchase shares of common stock

229,499

250,000

Warrant exercise price per share

$ 1.375

Warrnts exercised on cashless basis

$ 100

Proceeds from Issuance of Common Stock

$ 6,275,164

Stock issued for exercised of options, granted

1,532,500

1,340,000

Aggregate pro rata units

832,022

832,022

Fair market value of warrant

$ 4,299,649

$ 4,447,982

Share-based Payment Arrangement, Expense

865,111

$ 1,833,292

Restricted Stock or Unit Expense

$ 33,333

Common Stock [Member]

Class of Warrant or Right [Line Items]

Stock issued during period, shares, new issues

5,600,192

Stock issued during period, value, new issues

$ 5,600

Stock issued during period, shares, services

215,000

Stock issued during period services, value

$ 215

Issuance of common stock for acquisition, shares

4,600,000

10,000,000

Stock issued during period acquisition, value

$ 4,600

$ 10,000

Warrant [Member]

Class of Warrant or Right [Line Items]

Fair market value of warrant

$ 253,749

Warrant One [Member]

Class of Warrant or Right [Line Items]

Warrant to purchase shares of common stock

168,008

Fair market value of warrant

$ 152,249

Warrant Two [Member]

Class of Warrant or Right [Line Items]

Warrant to purchase shares of common stock

112,006

Fair market value of warrant

$ 101,500

Fair market value of warrant per share

$ 0.9062

Two Warrants [Member]

Class of Warrant or Right [Line Items]

Warrant term

5 years

Warrant exercise price per share

$ 1.375

Class A Warrants [Member]

Class of Warrant or Right [Line Items]

Warrant to purchase shares of common stock

29,978

New Class C Warrants [Member]

Class of Warrant or Right [Line Items]

Warrants exercisable term

5 years

Other Warrants [Member]

Class of Warrant or Right [Line Items]

Warrant to purchase shares of common stock

230,000

Warrant exercise price per share

$ 1.39

Warrants exercisable term

4 years 8 months 26 days

Fair market value of warrant

$ 368,287

Stock Incentive Plan [Member]

Class of Warrant or Right [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized

5,300,000

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant

1,649,057

Consulting Agreement [Member]

Class of Warrant or Right [Line Items]

Stock issued during period, shares, services

20,000

Shares issued, price per share

$ 1.25

Warrant to purchase shares of common stock

36,364

Warrant exercise price per share

$ 1.375

Unit Purchase Agreement [Member] | Class A Warrants [Member]

Class of Warrant or Right [Line Items]

Warrant to purchase shares of common stock

469,978

Warrant exercise price per share

$ 3.13

Warrants exercisable term

5 years

Unit Purchase Agreement [Member] | Class B Warrants [Member]

Class of Warrant or Right [Line Items]

Warrant to purchase shares of common stock

469,978

Warrant exercise price per share

$ 5

Warrants exercisable term

5 years

Unit Purchase Agreement [Member] | Class C Warrants [Member]

Class of Warrant or Right [Line Items]

Warrant to purchase shares of common stock

197,777

Warrant exercise price per share

$ 2.25

Warrants exercisable term

5 years

Aggregate pro rata units

1,045,549

Unit Purchase Agreement [Member] | New Class C Warrants [Member]

Class of Warrant or Right [Line Items]

Warrant to purchase shares of common stock

6,857,143

6,857,143

Warrant exercise price per share

$ 2.25

$ 2.25

Warrants exercisable term

5 years

Exchange Agreement [Member] | New Class C Warrants [Member]

Class of Warrant or Right [Line Items]

Warrant exercise price per share

$ 2.25

$ 2.25

Aggregate pro rata units

1,664,044

1,664,044

Second Tranche [Member]

Class of Warrant or Right [Line Items]

Stock issued during period, shares, new issues

990,208

Stock issued during period, value, new issues

$ 1,237,760

Proceeds from Issuance of Common Stock

$ 1,116,566

Soma Acquisition [Member]

Class of Warrant or Right [Line Items]

Issuance of common stock for acquisition, shares

10,000,000

Stock issued during period acquisition, value

$ 12,500,000

Somahlution Inc [Member] | Common Stock [Member]

Class of Warrant or Right [Line Items]

Issuance of common stock for acquisition, shares

10,000,000

Somahlution Inc [Member] | Warrant [Member]

Class of Warrant or Right [Line Items]

Issuance of common stock for acquisition, shares

3,000,000

Warrant exercise price per share

$ 5

Fair market value of warrant

$ 1,200,000

Fair market value of warrant per share

$ 0.40

Somahlution Inc [Member] | Warrant One [Member]

Class of Warrant or Right [Line Items]

Warrant term

5 years

Common Stock Conversion Debt [Member]

Class of Warrant or Right [Line Items]

Stock issued during period, shares, conversion of convertible securities

64,057

Common Stock Conversion Dbebt [Member]

Class of Warrant or Right [Line Items]

Stock issued during period, value, conversion of convertible securities

$ 59,453

Consultant [Member]

Class of Warrant or Right [Line Items]

Stock issued during period, shares, services

20,000

15,000

Stock issued during period services, value

$ 25,000

$ 15,150

Bruce Harmon [Member]

Class of Warrant or Right [Line Items]

Restricted stock issued during period

40,000

Directors, Senior Officers and Consultants [Member]

Class of Warrant or Right [Line Items]

Number of restricted share awards granted

350,000

Value of restricted share awards granted

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Related party transactions owned	$ 1,132,634
Proceeds from related party and shareholders debt	168,907
Related party transactions, administrative and general expenses	41,956
Related party transaction, amounts of transaction	92,356
Professional expense	2,269,756	1,153,731
Related party transactions, professional expenses	50,400
Prepaid royalties	339,091	344,321
Mr Richmond [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Related party transactions, administrative and general expenses	368,500
Related party transaction, amounts of transaction	168,907
Frank Maresca [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Proceeds from related party and shareholders debt	95,000
Related party transactions, administrative and general expenses	198,841
Related party transaction, amounts of transaction	871,371
Professional expense	$ 360,000	$ 180,000

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	Aug. 19, 2021	Jul. 13, 2019	Jul. 16, 2015	Dec. 31, 2021	Dec. 31, 2020	Aug. 03, 2020
Loss Contingencies [Line Items]
Consideration payment on legal matters			$ 9,450,000
Salary and wage				$ 2,887,309	$ 915,210
Issuance of stock options				1,532,500	1,340,000
Shares issued, price per share						$ 1.25
Royalties percentage				10.00%
Duragraft [Member]
Loss Contingencies [Line Items]
Sale of asset percentage				15.00%
Duragraft [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Net proceeds from sale of asset				$ 20,000,000
UNITED STATES | First 50,000,000 [Member]
Loss Contingencies [Line Items]
Royalties percentage				5.00%
UNITED STATES | 50,000,000 Up to 200,000,000 [Member]
Loss Contingencies [Line Items]
Royalties percentage				4.00%
UNITED STATES | Over 200,000,000 [Member]
Loss Contingencies [Line Items]
Royalties percentage				2.00%
Non-US [Member] | First 50,000,000 [Member]
Loss Contingencies [Line Items]
Royalties percentage				6.00%
Non-US [Member] | 50,000,000 Up to 200,000,000 [Member]
Loss Contingencies [Line Items]
Royalties percentage				4.00%
Non-US [Member] | Over 200,000,000 [Member]
Loss Contingencies [Line Items]
Royalties percentage				2.00%
July 13, 2022 [Member]
Loss Contingencies [Line Items]
Salary and wage		$ 30,000
July 13, 2021 [Member]
Loss Contingencies [Line Items]
Issuance of stock options		250,000
Shares issued, price per share		$ 1.50
Campbell [Member]
Loss Contingencies [Line Items]
Damages sought, value	$ 30,000
Harmon [Member]
Loss Contingencies [Line Items]
Damages sought, value	$ 50,000

Schedule of Net Loss Domestic a

Schedule of Net Loss Domestic and Foreign Jurisdictions (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Total	$ (10,997,929)	$ (5,845,053)
UNITED STATES
Total	(10,997,929)	(5,845,053)
INTERNATIONAL [Member]
Total

Schedule of Income Tax Expense

Schedule of Income Tax Expense (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Tax expense (benefit) at the statutory rate	$ (2,309,565)	$ (1,227,461)
Non-deductible items	620,855	384,991
Deferred true-ups	(119,782)	124,206
Change in valuation allowance	(2,309,565)	718,264
Total

Schedule of Deferred Tax Assets

Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Deferred tax assets:
Net operating loss carryforward	$ 8,758,337	$ 6,504,000
Lease liability	277,142	277,000
Deferred tax assets before valuation allowance	9,035,479	6,781,000
Less: deferred tax asset valuation allowance	(5,093,324)	(3,284,382)
Total deferred tax asset after valuation allowance	3,942,155	3,496,618
Deferred tax liabilities:
Intangible assets	(3,665,013)	(3,219,618)
Fixed assets	(277,142)	(277,000)
Total deferred tax liabilities	3,942,155	3,496,618
Total net deferred tax asset (liability)

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating Loss Carryforwards [Line Items]
Net operating loss carry forwards	$ 41,706,000	$ 30,971,000
Net operating loss carryforwards expiration	expected to expire at various times through 2041
Federal income tax rate	21.00%	21.00%
Deferred tax assets, valuation allowance	$ 5,093,324	$ 3,284,382
Operating loss carryforward description	The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows NOLs incurred in 2018, 2019, and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes.
2018 Through 2025 [Member]
Operating Loss Carryforwards [Line Items]
Effective tax rate	10.50%
After 2025 [Member]
Operating Loss Carryforwards [Line Items]
Effective tax rate	13.125%

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)

Mar. 15, 2022

Feb. 14, 2022

Jan. 26, 2022

Jan. 24, 2022

Jan. 13, 2022

Dec. 22, 2021

Jun. 08, 2020

Apr. 06, 2020

Jan. 09, 2020

Dec. 31, 2020

Dec. 31, 2021

Aug. 03, 2020

Subsequent Event [Line Items]

Shares issued, price per share

$ 1.25

Warrants to purschase common stock

250,000

229,499

Stock issued during ther period, share

4,600,000

20,000

160,000

125,000

Stike price per share

$ 1.375

Common Stock [Member]

Subsequent Event [Line Items]

Common stock issued for services, shares

215,000

Stock issued during ther period, share

5,600,192

Subsequent Event [Member] | Consultants [Member]

Subsequent Event [Line Items]

Common stock issued for services, shares

22,857

Shares issued, price per share

$ 1.75

Principal amount

$ 40,000

Subsequent Event [Member] | Consultants [Member] | Common Class C [Member]

Subsequent Event [Line Items]

Warrants to purschase common stock

45,714

Subsequent Event [Member] | Two Unrelated Investors [Member]

Subsequent Event [Line Items]

Shares issued, price per share

$ 1.75

Principal amount

$ 278,678

Stock issued during ther period, share

159,245

Subsequent Event [Member] | Two Unrelated Investors [Member] | Common Class C [Member]

Subsequent Event [Line Items]

Warrants to purschase common stock

218,490

Subsequent Event [Member] | Bradely Richmond [Member]

Subsequent Event [Line Items]

Common stock issued for services, shares

171,429

Shares issued, price per share

$ 1.75

Principal amount

$ 300,000

Stock issued during ther period, share

300,000

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted

300,000

Stike price per share

$ 0.01

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised

300,000

Subsequent Event [Member] | Bradely Richmond [Member] | Common Stock [Member]

Subsequent Event [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted

300,000

Subsequent Event [Member] | Bradely Richmond [Member] | Common Class C [Member]

Subsequent Event [Line Items]

Warrants to purschase common stock

342,000